US20070142270A1 - Aryl Sulfonic Pyridoxines as Antiplatelet Agents - Google Patents
Aryl Sulfonic Pyridoxines as Antiplatelet Agents Download PDFInfo
- Publication number
- US20070142270A1 US20070142270A1 US11/672,140 US67214007A US2007142270A1 US 20070142270 A1 US20070142270 A1 US 20070142270A1 US 67214007 A US67214007 A US 67214007A US 2007142270 A1 US2007142270 A1 US 2007142270A1
- Authority
- US
- United States
- Prior art keywords
- defined above
- aryl
- alkyl
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C(C)N=CC([3*])=C1[2*] Chemical compound [1*]C1=C(C)N=CC([3*])=C1[2*] 0.000 description 29
- FVTLTODGWABHOW-UHFFFAOYSA-N CC.CC.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 Chemical compound CC.CC.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 FVTLTODGWABHOW-UHFFFAOYSA-N 0.000 description 2
- SNJWAQUKFXGRRW-UHFFFAOYSA-N C.C.CC.CC.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 Chemical compound C.C.CC.CC.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 SNJWAQUKFXGRRW-UHFFFAOYSA-N 0.000 description 1
- FZYVCOPFDSZWFU-UHFFFAOYSA-N C.CC(C)(C)NS(=O)(=O)C1=C(C2=CC=CC(N)=C2)C=CC=C1.CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.[H]C(=O)C1=C(CO)C=CC(C)=C1O Chemical compound C.CC(C)(C)NS(=O)(=O)C1=C(C2=CC=CC(N)=C2)C=CC=C1.CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.[H]C(=O)C1=C(CO)C=CC(C)=C1O FZYVCOPFDSZWFU-UHFFFAOYSA-N 0.000 description 1
- OXJNMFVXCXURAI-UHFFFAOYSA-N C.CC(C)(C)NS(=O)(=O)C1=C(C2=CC=CC(N)=C2)C=CC=C1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)=CC=C2)C=N1.[H]C(=O)C1=C2COC(C)(C)OC2=C(C)N=C1 Chemical compound C.CC(C)(C)NS(=O)(=O)C1=C(C2=CC=CC(N)=C2)C=CC=C1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)=CC=C2)C=N1.[H]C(=O)C1=C2COC(C)(C)OC2=C(C)N=C1 OXJNMFVXCXURAI-UHFFFAOYSA-N 0.000 description 1
- XWCNAIRTWMVMOM-UHFFFAOYSA-M C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(C(=O)O[Na])C=C1.CC1=C2OC(C)(C)OCC2=C(CN)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1 Chemical compound C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(C(=O)O[Na])C=C1.CC1=C2OC(C)(C)OCC2=C(CN)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1 XWCNAIRTWMVMOM-UHFFFAOYSA-M 0.000 description 1
- PVZXQSHLFAXABB-UHFFFAOYSA-N C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N)C(F)=C1.[H]C(=O)C1=C(CO)C=NC(C)=C1O.[H]N(CC1=C(CO)C=NC(C)=C1O)C1=C(F)C=C(C2=CC=CC=C2S(=O)(=O)NC(C)(C)C)C=C1 Chemical compound C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N)C(F)=C1.[H]C(=O)C1=C(CO)C=NC(C)=C1O.[H]N(CC1=C(CO)C=NC(C)=C1O)C1=C(F)C=C(C2=CC=CC=C2S(=O)(=O)NC(C)(C)C)C=C1 PVZXQSHLFAXABB-UHFFFAOYSA-N 0.000 description 1
- SBUSEPMKCKCXCT-UHFFFAOYSA-N C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N)C=C1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.[H]C(=O)C1=C2COC(C)(C)OC2=C(C)N=C1 Chemical compound C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N)C=C1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.[H]C(=O)C1=C2COC(C)(C)OC2=C(C)N=C1 SBUSEPMKCKCXCT-UHFFFAOYSA-N 0.000 description 1
- UBQGRVORGYGYQZ-UHFFFAOYSA-N C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N)C=C1.[H]C(=O)C1=C(CO)C=NC(C)=C1O.[H]N(CC1=C(CO)C=NC(C)=C1O)C1=CC=C(C2=CC=CC=C2S(=O)(=O)NC(C)(C)C)C=C1 Chemical compound C.CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N)C=C1.[H]C(=O)C1=C(CO)C=NC(C)=C1O.[H]N(CC1=C(CO)C=NC(C)=C1O)C1=CC=C(C2=CC=CC=C2S(=O)(=O)NC(C)(C)C)C=C1 UBQGRVORGYGYQZ-UHFFFAOYSA-N 0.000 description 1
- AZJQESKKDUYZGI-UHFFFAOYSA-N CC(C)(C)NS(=O)(=O)C1=C(B(O)O)C=CC=C1.CC(C)(C)NS(=O)(=O)C1=C(C2=CC=CC(N)=C2)C=CC=C1.NC1=CC(Br)=CC=C1 Chemical compound CC(C)(C)NS(=O)(=O)C1=C(B(O)O)C=CC=C1.CC(C)(C)NS(=O)(=O)C1=C(C2=CC=CC(N)=C2)C=CC=C1.NC1=CC(Br)=CC=C1 AZJQESKKDUYZGI-UHFFFAOYSA-N 0.000 description 1
- FADKNXYTMUUNSB-UHFFFAOYSA-N CC(C)(C)NS(=O)(=O)C1=C(B(O)O)C=CC=C1.CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(Br)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 Chemical compound CC(C)(C)NS(=O)(=O)C1=C(B(O)O)C=CC=C1.CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(Br)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 FADKNXYTMUUNSB-UHFFFAOYSA-N 0.000 description 1
- CMYJUFJAIGZQCD-UHFFFAOYSA-N CC(C)(C)NS(c(cccc1)c1-c(cc1)ccc1NCc1c(CO)c(OCc2cc(C#N)ccc2)c(C)nc1)(=O)=O Chemical compound CC(C)(C)NS(c(cccc1)c1-c(cc1)ccc1NCc1c(CO)c(OCc2cc(C#N)ccc2)c(C)nc1)(=O)=O CMYJUFJAIGZQCD-UHFFFAOYSA-N 0.000 description 1
- VQXHLPZLXMLAJR-UHFFFAOYSA-N CC(C)(C)NS(c(cccc1)c1-c1ccc(NCc2c(CO)c(OCc3cc(C#N)ccc3)c(C)nc2)nc1)(=O)=O Chemical compound CC(C)(C)NS(c(cccc1)c1-c1ccc(NCc2c(CO)c(OCc3cc(C#N)ccc3)c(C)nc2)nc1)(=O)=O VQXHLPZLXMLAJR-UHFFFAOYSA-N 0.000 description 1
- XDAGXZXKTKRFMT-UHFFFAOYSA-N CC(C)=N Chemical compound CC(C)=N XDAGXZXKTKRFMT-UHFFFAOYSA-N 0.000 description 1
- GMQUATPNYKZSPU-UHFFFAOYSA-N CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(N)(=O)=O)=CC=C2)=C(CO)C=N1 Chemical compound CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(N)(=O)=O)=CC=C2)=C(CO)C=N1 GMQUATPNYKZSPU-UHFFFAOYSA-N 0.000 description 1
- CBBLUOIEQDUJLC-UHFFFAOYSA-N CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)C=C1 Chemical compound CC1=C(O)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)C=C1 CBBLUOIEQDUJLC-UHFFFAOYSA-N 0.000 description 1
- PSEKFKYLDIEFNT-UHFFFAOYSA-N CC1=C(O)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)=C(CO)C=N1.CC1=C(OCC2=CC(C#N)=CC=C2)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)=C(CO)C=N1 Chemical compound CC1=C(O)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)=C(CO)C=N1.CC1=C(OCC2=CC(C#N)=CC=C2)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)=C(CO)C=N1 PSEKFKYLDIEFNT-UHFFFAOYSA-N 0.000 description 1
- NCSPADHEGGBUTR-UHFFFAOYSA-N CC1=C(O)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2F)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2F)C=C1 Chemical compound CC1=C(O)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2F)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2F)C=C1 NCSPADHEGGBUTR-UHFFFAOYSA-N 0.000 description 1
- KBKMCTHCRVXYFO-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(N)(=O)=O)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(N)(=O)=O)C=C2)C=N1 KBKMCTHCRVXYFO-UHFFFAOYSA-N 0.000 description 1
- WYVXBVAOHWXXSN-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1 WYVXBVAOHWXXSN-UHFFFAOYSA-N 0.000 description 1
- AITCQHVDMBHFHW-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1 AITCQHVDMBHFHW-UHFFFAOYSA-N 0.000 description 1
- VOHBLJYGEJUURN-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=CC(C3=C(S(N)(=O)=O)C=CC=C3)=CC=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)=CC=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC2=CC(C3=C(S(N)(=O)=O)C=CC=C3)=CC=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)=CC=C2)C=N1 VOHBLJYGEJUURN-UHFFFAOYSA-N 0.000 description 1
- QDCBUDBEHVTYCE-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=CC=C(C(=N)N)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC2=CC=C(C3=CC=C(C(=N)N)C=C3)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC2=CC=C(C(=N)N)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC2=CC=C(C3=CC=C(C(=N)N)C=C3)C=C2)C=N1 QDCBUDBEHVTYCE-UHFFFAOYSA-N 0.000 description 1
- VATQCJBDZKZGCD-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1 VATQCJBDZKZGCD-UHFFFAOYSA-N 0.000 description 1
- UWXMDFMTTXIVBX-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 UWXMDFMTTXIVBX-UHFFFAOYSA-N 0.000 description 1
- PUOFSBXKALRCCU-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.[C-]#[N+]C1=CC(COC2=C(C)N=CC(CNC3=CC=C(C4=C(S(=O)(=O)NC(C)(C)C)C=CC=C4)C=C3)=C2CO)=CC=C1 Chemical compound CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.[C-]#[N+]C1=CC(COC2=C(C)N=CC(CNC3=CC=C(C4=C(S(=O)(=O)NC(C)(C)C)C=CC=C4)C=C3)=C2CO)=CC=C1 PUOFSBXKALRCCU-UHFFFAOYSA-N 0.000 description 1
- YSIIBQJKDXBPCM-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CNC3=CC=C(C4=C(S(=O)(=O)NC(C)(C)C)C=CC=C4)C=C3)=C2CO)C=C1 Chemical compound CC1=C(O)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CNC3=CC=C(C4=C(S(=O)(=O)NC(C)(C)C)C=CC=C4)C=C3)=C2CO)C=C1 YSIIBQJKDXBPCM-UHFFFAOYSA-N 0.000 description 1
- RCMRHTRHKHXACA-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 RCMRHTRHKHXACA-UHFFFAOYSA-N 0.000 description 1
- LAMRDQMROVNHMP-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1 LAMRDQMROVNHMP-UHFFFAOYSA-N 0.000 description 1
- KFINGFUUJVZCSG-UHFFFAOYSA-N CC1=C(O)C(CO)=C(CNC2=NC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC2=NC=C(C3=CC=CC=C3S(N)(=O)=O)C=C2)C=N1 Chemical compound CC1=C(O)C(CO)=C(CNC2=NC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(O)C(CO)=C(CNC2=NC=C(C3=CC=CC=C3S(N)(=O)=O)C=C2)C=N1 KFINGFUUJVZCSG-UHFFFAOYSA-N 0.000 description 1
- YJSVKAJQPKEYIU-UHFFFAOYSA-N CC1=C(OCC2=CC(C#N)=CC=C2)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)=C(CO)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)=C(CO)C=N1 Chemical compound CC1=C(OCC2=CC(C#N)=CC=C2)C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)=C(CO)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)=C(CO)C=N1 YJSVKAJQPKEYIU-UHFFFAOYSA-N 0.000 description 1
- KLSQYGJGIAJHMA-UHFFFAOYSA-N CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(N)(=O)=O)C=C2)C=N1 Chemical compound CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)C=C2)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CO)=C(CNC(=O)C2=CC=C(C3=CC=CC=C3S(N)(=O)=O)C=C2)C=N1 KLSQYGJGIAJHMA-UHFFFAOYSA-N 0.000 description 1
- TWHVVFIABIKCIU-UHFFFAOYSA-N CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CO)=C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1 Chemical compound CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CO)=C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1 TWHVVFIABIKCIU-UHFFFAOYSA-N 0.000 description 1
- JKRDELFTTGHDIF-UHFFFAOYSA-N CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CO)=C(CNC2=NC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1 Chemical compound CC1=C(OCC2=CC(C#N)=CC=C2)C(CO)=C(CNC2=NC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2)C=N1.CC1=C(OCC2=CC(C(=N)N)=CC=C2)C(CO)=C(CNC2=NC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1 JKRDELFTTGHDIF-UHFFFAOYSA-N 0.000 description 1
- BSWKKPUHMKEEBV-UHFFFAOYSA-N CC1=C(OCC2=CC=C(C(=N)N)C=C2)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)C=C1 Chemical compound CC1=C(OCC2=CC=C(C(=N)N)C=C2)C(CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC(C3=CC=CC=C3S(=O)(=O)NC(C)(C)C)=CC=C2)C=C1 BSWKKPUHMKEEBV-UHFFFAOYSA-N 0.000 description 1
- XWUVWBIOWHELCZ-UHFFFAOYSA-N CC1=C(OCC2=CC=C(C(=N)N)C=C2)C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2F)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2F)C=C1 Chemical compound CC1=C(OCC2=CC=C(C(=N)N)C=C2)C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2F)=C(CO)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CO)=C2CNC2=CC=C(C3=C(S(=O)(=O)NC(C)(C)C)C=CC=C3)C=C2F)C=C1 XWUVWBIOWHELCZ-UHFFFAOYSA-N 0.000 description 1
- KRVAUPWYGWREKY-UHFFFAOYSA-N CC1=C(OCC2=CC=C(C(=N)N)C=C2)C(CO)=C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CNC3=CC=C(C4=C(S(=O)(=O)NC(C)(C)C)C=CC=C4)C=C3)=C2CO)C=C1 Chemical compound CC1=C(OCC2=CC=C(C(=N)N)C=C2)C(CO)=C(CNC2=CC=C(C3=C(S(N)(=O)=O)C=CC=C3)C=C2)C=N1.[C-]#[N+]C1=CC=C(COC2=C(C)N=CC(CNC3=CC=C(C4=C(S(=O)(=O)NC(C)(C)C)C=CC=C4)C=C3)=C2CO)C=C1 KRVAUPWYGWREKY-UHFFFAOYSA-N 0.000 description 1
- DKPOYUSLSHWDGX-UHFFFAOYSA-N CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(Br)C=C2)C=N1.[H]C(=O)C1=C2COC(C)(C)OC2=C(C)N=C1 Chemical compound CC1=C2OC(C)(C)OCC2=C(CNC2=NC=C(Br)C=C2)C=N1.[H]C(=O)C1=C2COC(C)(C)OC2=C(C)N=C1 DKPOYUSLSHWDGX-UHFFFAOYSA-N 0.000 description 1
- NJHFFKOYRDQOCN-UHFFFAOYSA-N Cc(ncc(CNc(nc1)ccc1-c1ccccc1S(N)(=O)=O)c1CO)c1OCc1cc(C(N)=N)ccc1 Chemical compound Cc(ncc(CNc(nc1)ccc1-c1ccccc1S(N)(=O)=O)c1CO)c1OCc1cc(C(N)=N)ccc1 NJHFFKOYRDQOCN-UHFFFAOYSA-N 0.000 description 1
- UGMDCUVYIBSSRA-UHFFFAOYSA-N Cc1ncc(CNc(cc2)ccc2-c2ccccc2S(N)(=O)=O)c(CO)c1OCc1cc(C(N)=N)ccc1 Chemical compound Cc1ncc(CNc(cc2)ccc2-c2ccccc2S(N)(=O)=O)c(CO)c1OCc1cc(C(N)=N)ccc1 UGMDCUVYIBSSRA-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N OCc1ccccc1 Chemical compound OCc1ccccc1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- YUFJYHRUEUJWGN-UHFFFAOYSA-N [H]N(CC1=C(CO)C=NC(C)=C1O)C1=CC=C(C2=CC=CC=C2S(=O)(=O)NC(C)(C)C)C=C1.[H]N(CC1=C(CO)C=NC(C)=C1O)C1=CC=C(C2=CC=CC=C2S(N)(=O)=O)C=C1 Chemical compound [H]N(CC1=C(CO)C=NC(C)=C1O)C1=CC=C(C2=CC=CC=C2S(=O)(=O)NC(C)(C)C)C=C1.[H]N(CC1=C(CO)C=NC(C)=C1O)C1=CC=C(C2=CC=CC=C2S(N)(=O)=O)C=C1 YUFJYHRUEUJWGN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Definitions
- This invention relates to aryl sulfonic pyridoxines and methods of treating cardiovascular, cerebrovascular, and cardiovascular related diseases or symptoms by administering pharmaceutical compositions comprising an aryl sulfonic pyridoxine.
- Thrombosis the development of blood clots within arterial vessels, is due to a complex mechanism involving the activation of both platelet aggregation and the coagulation protease cascade ( Ann. Intern Med . (2001) 134: 224-38 ; N. Engl. J. Med . (2002) 347: 5-12 ; Thromb. Haemost . (2002) 86: 51-6).
- the pathways involved normally inhibit blood loss after vessel injury, but in thrombosis and related conditions, these reactions are inappropriately initiated and propagated.
- thrombosis is initiated by the release of mediators such as tissue factor (TF), von Willebrand Factor (vWF) ( J. Thromb. Haemost . (2003) 1: 1602-1612), and collagen from ruptured atherosclerotic plaques or from damaged blood vessels. Collagen and vWF bind to receptors on platelets and initiate their activation. Once activated, platelets release secretory granules containing ADP, ATP, and calcium ( Curr. Opin. Hematol . (2001) ⁇ : 270-276). Activated platelets also synthesize and release thromboxane. The released ADP and thromboxane bind to receptors on the platelets to further propagate platelet activation. Once platelets are activated they start aggregating to initiate clot formation.
- mediators such as tissue factor (TF), von Willebrand Factor (vWF) ( J. Thromb. Haemost . (2003) 1: 1602-1612), and collagen from rupture
- Tissue factor (TF) transiently exposed at a vascular site damaged either mechanically or by inflammatory processes, is responsible for initiating the coagulation cascade leading to thrombus formation (Giesen et al. (1999) Proc. Natl. Acad. Sci. USA 96: 2311-2315).
- thrombin Association of TF with activated factor VII (fvIIa) on the membrane surface triggers a complex enzyme amplification network of events that leads to the generation of thrombin and subsequently, conversion of fibrinogen to fibrin.
- thrombin amplifies its own production and activates platelets via its enzymatic action on platelet protease-activated receptors PAR-1 and PAR-4 (Lane (2005) Blood 106: 2605-2612).
- One embodiment of the invention includes aryl sulfonic pyridoxines, compositions containing the aryl sulfonic pyridoxines, and methods of treatment using therapeutically effective amounts of aryl sulfonic pyridoxines.
- Compounds and compositions of the invention can be used to treat cardiovascular, cerebovascular or related diseases and symptoms thereof.
- R 1 is —OH, —O-alkyl, —(CH 2 ) n′ OH where n′ is an integer from 1 to 8, alkyl, cycloalkyl, or O-alkyl-aryl-R 4 , where R 4 is —CN or amidine;
- R 2 is alkyl; —(CH 2 ) n′ OH where n′ is as defined above; —(CH 2 ) n COOH where n is an integer from 0 to 8; —(CH 2 ) n COO(CH 2 ) n CH 3 where n is as defined above; or R 5 where R 5 is (CH 2 ) n -aryl-R 6 where n is as defined above and R 6 is SO 2 NH 2 or SO 2 NHC(CH 3 ) 3 ; (CH 2 ) n -aryl-aryl-R 6 , where n and R 6 are as defined above; (CH 2 ) n —NH-aryl-aryl-R 6 , where n and R 6 are as defined above; (CH 2 ) n —NH—CO-aryl-aryl-R 6 , where n and R 6 are as defined above; or —(CH 2 ) n —NH-aryl-R 6 , where n and R 6 are as
- R 3 is alkyl; —(CH 2 ) n′ OH where n′ is as defined above; or R 5 where R 5 is (CH 2 ) n —NH-aryl-R 6 , where n and R 6 are as defined above; (CH 2 ) n —NH—CO-aryl-R 6 where n and R 6 are as defined above; (CH 2 ) n —NH-aryl-aryl-R 6 where n and R 6 are as defined above; or (CH 2 ) n —NH—CO-aryl-aryl-R 6 where n and R 6 are as defined above;
- R 1 and R 2 when taken together form compounds of formula II, wherein R 7 and R 8 are independently H or CH 3 , and R 5 is as defined above; or a pharmaceutically acceptable salt thereof.
- the invention provides compounds of the formula I:
- R 1 is —OH, —O-alkyl, —(CH 2 ) n′ OH where n′ is an integer from 1 to 8, alkyl, cycloalkyl, or O-alkyl-aryl-R 4 , where R 4 is —CN or amidine;
- R 2 is alkyl; —(CH 2 ) n′ OH where n′ is as defined above; —(CH 2 ) n′ COOH where n is an integer from 0 to 8; —(CH 2 ) n COO(CH 2 ) n CH 3 where n is as defined above; or R 5 where R 5 is (CH 2 ) n -aryl-R 6 where n is as defined above and R 6 is SO 2 NH 2 or SO 2 NHC(CH 3 ) 3 ; (CH 2 ) n -aryl-aryl-R 6 , where n and R 6 are as defined above; (CH 2 ) n —NH-aryl-aryl-R 6 , where n and R 6 are as defined above; (CH 2 ) n —NH—CO-aryl-aryl-R 6 , where n and R 6 are as defined above; or —(CH 2 ) n —NH-aryl-aryl-R 6 where n and R 6
- R 3 is alkyl; —(CH 2 ) n′ OH where n′ is as defined above; or R 5 where R 5 is (CH 2 ) n —NH-aryl-R 6 , where n and R 6 are as defined above; (CH 2 ) n —NH—CO-aryl-R 6 where n and R 6 are as defined above; (CH 2 ) n —NH-aryl-aryl-R 6 where n and R 6 are as defined above; or (CH 2 ) n —NH—CO-aryl-aryl-R 6 where n and R 6 are as defined above;
- R 7 and R 8 are independently H or CH 3 , and R 5 is as defined above;
- R 1 is OH; OCH 3 ; OCH 2 -(4-tert-Butyl-phenyl); or where R 4 is —CN or amidine;
- R 3 is (CH 2 ) m OH, where m is as defined above; or R 5 , where R 5 is as defined above;
- R 7 and R 8 are independently H or CH 3 ; and R 5 is as defined above;
- alkyl includes a saturated linear or branched hydrocarbon radical. In one embodiment, alkyl has from 1 to 8 carbon atoms. In another embodiment, alkyl has from 1 to 6 carbon atoms. In another embodiment, alkyl has from 1 to 4 carbon atoms. In one embodiment, alkyl has 1 carbon.
- the alkyl group may optionally be substituted with one or more substituents such as fluorine, chlorine, alkoxy groups having from 1 to 8 carbon atoms (e.g., methoxy or ethoxy), or amido groups having from 1 to 8 carbon atoms, such as acetamido. These substituents may themselves be substituted with one or more functional groups such as hydroxy groups, carboxy groups, acetoxy groups, or halogens.
- cycloalkyl refers to a cyclic hydrocarbon having from 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, such as, for example, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
- aryl means a mono- or poly-nuclear aromatic hydrocarbon radical.
- aryl groups include, but are not limited to aromatic hydrocarbons such as a phenyl group or a naphthyl group.
- the aromatic group may optionally be substituted with one or more substituents such as fluorine, chlorine, alkyl groups having from 1 to 10 carbon atoms (e.g., methyl or ethyl), alkoxy groups having from 1 to 8 carbon atoms (e.g., methoxy or ethoxy), alkoxyalkyl groups having from 1 to 8 carbon atoms and one or more oxygen atoms, or amido groups having from 1 to 8 carbon atoms, such as acetamido.
- substituents may themselves be substituted with one or more functional groups such as hydroxy groups, carboxy groups, acetoxy groups, or halogens.
- aryl is a phenyl group or a naphthyl group that is either unsubstituted or substituted.
- aryl is a heteroaryl in which one or more of the carbon atoms of an aromatic hydrocarbon is substituted with a nitrogen, sulfur, or oxygen.
- heteroaryl include, but are not limited to pyridine, pyrimidine, pyran, dioxin, oxazine, and oxathiazine.
- the heteroaryl may optionally be substituted with functional groups such as hydroxy groups, carboxy groups, halogens, and amino groups.
- amidine means a group having the formula
- the invention also includes pharmaceutically acceptable salts of the compounds of the invention.
- the compounds of the invention are capable of forming both pharmaceutically acceptable acid addition and/or base salts.
- Pharmaceutically acceptable acid addition salts of the compounds of the invention include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and di-carboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
- Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
- salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine, etc. (see Berge et al., J. Pharmaceutical Science, 66: 1-19 (1977).
- pharmaceutically acceptable salts also includes any pharmaceutically acceptable base salt including, but not limited to, amine salts, trialkyl amine salts and the like. Such salts can be formed quite readily by those skilled in the art using standard techniques.
- the acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
- the free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner.
- the free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.
- Base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations include, but are not limited to, sodium, potassium, magnesium, and calcium. Examples of suitable amines are N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.
- Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)- .
- the present invention is meant to include all such possible diastereomers and enantiomers as well as their racemic and optically pure forms.
- Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- the compounds described herein contain centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise all tautomeric forms are intended to be included.
- the compounds are generally prepared by combining an aldehyde or a carboxylate with an amine group to produce an elaborated pyridine structure.
- the general scheme of preparing the compounds of the formulae comprise protecting the hydroxyl groups at R 1 and R 2 of pyridoxine with known blocking groups such as esters, ethers, cyclic acetals, cyclic ketals, etc. and elaborating R 3 through generating an aldehyde, acid, halide, or amine functionality as shown in Schemes 1-4.
- R 3 may be an aryl or biaryl containing a nitro, amino, or cyano group that can be converted to an amidine by known chemical procedures.
- protecting R 1 and R 3 with known blocking groups such as esters, ethers, cyclic acetals, cyclic ketals, etc. and elaborating R 2 through generating an aldehyde, acid, halide, or amine functionality can be achieved through the same general scheme as shown in Scheme 5.
- Cardiovascular or related diseases include, for example, cerebral ischemia, cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, hypertension, myocardial infarction, ischemia reperfusion injury, myocardial ischemia, congestive heart failure, blood coagulation disorders, cardiac hypertrophy, and platelet aggregation. Cardiovascular or related diseases also include diseases that arise from thrombotic and prothrombotic states in which the coagulation cascade is activated such as, for example, deep vein thrombosis, disseminated intravascular coagulopathy, and pulmonary embolism.
- Heart failure is a pathophysiological condition in which the heart is unable to pump blood at a rate commensurate with the requirement of the metabolizing tissues or can do so only from an elevated filling pressure (increased load). Thus, the heart has a diminished ability to keep up with its workload. Over time, this condition leads to excess fluid accumulation, such as peripheral edema, and is referred to as congestive heart failure.
- myocardial hypertrophy i.e., enlargement of the heart muscle
- Hypertrophy permits the ventricle to sustain an increased load because the heart muscle can contract with greater force.
- a ventricle subjected to an abnormally elevated load for a prolonged period eventually fails to sustain an increased load despite the presence of ventricular hypertrophy, and pump failure can ultimately occur.
- Heart failure can arise from any disease that affects the heart and interferes with circulation.
- a disease that increases the heart muscle's workload such as hypertension
- Hypertension will eventually weaken the force of the heart's contraction.
- Hypertension is a condition in which there is an increase in resistance to blood flow through the vascular system. This resistance leads to increases in systolic pressure, diastolic blood pressure, or both.
- Hypertension places increased tension on the left ventricular myocardium, causing it to stiffen and hypertrophy, and accelerates the development of atherosclerosis in the coronary arteries.
- the combination of increased demand and lessened supply increases the likelihood of myocardial ischemia leading to myocardial infarction, sudden death, arrhythmias, and congestive heart failure.
- Ischemia is a condition in which an organ or a part of the body fails to receive a sufficient blood supply.
- an organ When an organ is deprived of a blood supply, it is said to be hypoxic. An organ will become hypoxic even when the blood supply temporarily ceases, such as during a surgical procedure or during temporary artery blockage.
- Ischemia initially leads to a decrease in or loss of contractile activity.
- myocardial ischemia When the organ effected is the heart, this condition is known as myocardial ischemia, and myocardial ischemia initially leads to abnormal electrical activity. This can generate an arrhythmia.
- myocardial ischemia When myocardial ischemia is of sufficient severity and duration, cell injury can progress to cell death—i.e., myocardial infarction—and subsequently to heart failure, hypertrophy, or congestive heart failure.
- Ischemic reperfusion of the organ occurs when blood flow resumes to an organ after temporary cessation.
- reperfusion of an ischemic myocardium can counter the effects of coronary occlusion, a condition that leads to myocardial ischemia.
- Ischemic reperfusion to the myocardium can lead to reperfusion arrhythmia or reperfusion injury.
- the severity of reperfusion injury is affected by numerous factors, such as, for example, duration of ischemia, severity of ischemia, and speed of reperfusion. Conditions observed with ischemia reperfusion injury include neutrophil infiltration, necrosis, and apoptosis.
- compositions containing at least one compound of the invention comprises a pharmaceutically acceptable carrier in combination with a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
- a pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate-buffered saline, and other carriers known in the art.
- Pharmaceutical compositions can also include additives such as, for example, stabilizers, antioxidants, colorants, excipients, binders, thickeners, dispersing agents, readsorpotion enhancers, buffers, surfactants, preservatives, emulsifiers, isotonizing agents, and diluents.
- Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.
- compositions containing a pharmaceutically acceptable carrier in combination with a therapeutic compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention are known to those of skill in the art. All methods can include the step of bringing the compound of the invention in association with the carrier and additives.
- the formulations generally are prepared by uniformly and intimately bringing the compound of the invention into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage forms.
- the compositions can be prepared according to techniques well known in the art of pharmaceutical formulation.
- the compositions can contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents.
- the compositions can contain microcrystalline cellulose, starch, magnesium stearate and lactose or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
- compositions can be prepared according to techniques well known in the art of pharmaceutical formulation.
- the compositions can be prepared as solutions in saline, using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons or other solubilizing or dispersing agents known in the art.
- compositions can be formulated according to techniques well-known in the art, using suitable dispersing or wetting and suspending agents, such as sterile oils, including synthetic mono- or di-glycerides, and fatty acids, including oleic acid.
- suitable dispersing or wetting and suspending agents such as sterile oils, including synthetic mono- or di-glycerides, and fatty acids, including oleic acid.
- compositions can be prepared by mixing with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ambient temperatures, but liquefy or dissolve in the rectal cavity to release the drug.
- a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ambient temperatures, but liquefy or dissolve in the rectal cavity to release the drug.
- treatment and “treating” include inhibiting, alleviating, and healing cardiovascular or related diseases or symptoms thereof. Treatment can be carried out by administering a therapeutically effective amount of at least one compound of the invention.
- a “therapeutically effective amount” as used herein includes a prophylactic amount, for example an amount effective for alleviating or healing the above mentioned diseases or symptoms thereof.
- a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention can be formulated into pharmaceutically acceptable unit dosage forms by conventional methods known in the pharmaceutical art.
- An effective but nontoxic quantity of the compound is employed in treatment.
- the compounds can be administered in enteral unit dosage forms, such as, for example, tablets, sustained-release tablets, enteric coated tablets, capsules, sustained-release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like. They can also be administered parenterally, such as, for example, subcutaneously, intramuscularly, intradermally, intramammarally, intravenously, and by other administrative methods known in the art.
- the ordinarily skilled physician or veterinarian will readily determine and prescribe the therapeutically effective amount of the compound to treat the disease for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained.
- the particular disease, the severity of the disease, the compound to be administered, the route of administration, and the characteristics of the mammal to be treated, for example, age, sex, and weight are considered in determining the effective amount to administer.
- Administering a therapeutic amount of a compound of the invention for treating cardiovascular or related diseases or symptoms thereof is in a range of about 0.1-100 mg/kg of a patient's body weight, more preferably in the range of about 0.5-50 mg/kg of a patient's body weight, per daily dose.
- the compound can be administered for periods of short and long duration. Although some individual situations can warrant to the contrary, short-term administration, for example, 30 days or less, of doses larger than 25 mg/kg of a patient's body weight is preferred to long-term administration. When long-term administration, for example, months or years, is required, the suggested dose usually does not exceed 25 mg/kg of a patient's body weight.
- a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable addition salt of a compound of the invention for treating the above-identified diseases or symptoms thereof can be administered prior to, concurrently with, or after the onset of the disease or symptom.
- a compound of the invention can be administered concurrently.
- “Concurrent administration” and “concurrently administering” as used herein includes administering a compound of the invention and another therapeutic agent in admixture, such as, for example, in a pharmaceutical composition or in solution, or separately, such as, for example, separate pharmaceutical compositions or solutions administered consecutively, simultaneously, or at different times but not so distant in time such that the compound of the invention and the other therapeutic agent cannot interact and a lower dosage amount of the active ingredient cannot be administered.
- a method for treating cardiovascular or related diseases comprising administering to a mammal a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable addition salt of a compound of the invention in a unit dosage form.
- the cardiovascular or related diseases that can be treated include hypertrophy, hypertension, congestive heart failure, heart failure subsequent to myocardial infarction, myocardial ischemia, cerebral ischemia, ischemia reperfusion injury, arrhythmia, myocardial infarction, blood coagulation, platelet aggregation, atherosclerosis, atrial fibrillation, or acute coronary syndrome.
- the cardiovascular disease treated is hypertrophy, congestive heart failure, arrhythmia, or ischemia reperfusion injury.
- Compounds of the invention may also be administered as anticoagulants to patients with heparin induced thrombocyotpenia (HIT).
- HIT heparin induced thrombocyotpenia
- Serine protease activity can be inhibited by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention.
- Compounds of the invention can be administered to inhibit serine protease activity in a mammal, thereby affecting varying disease states, including platelet aggregation.
- Compounds of the invention can inhibit serine proteases such as, but not limited to, trypsin, chymotrypsin, kallikrein, elastase, thrombin (Factor IIa), plasmin, Factors VIIa, IXa, Xa, XIa, XIIa, and protein C.
- the mammal is a human.
- Compounds of the invention can also be used to inhibit serine protease activity in vitro.
- Serine protease inhibitors can be useful for research and diagnostic purposes.
- compounds of the invention can inhibit serine protease activity in a monolayer of a cell culture following contact with the cells of said cell culture.
- compounds of the invention can be administered to inhibit non-mammalian serine proteases.
- the non-mammalian serine protease can be from microorganisms, including bacteria and viruses.
- Bacterial serine proteases include, but is not limited to, subtilisin (from Bacillus subtilis ).
- Viral serine proteases can be inhibitied by compounds disclosed herein, including, but not limited to, hepatitis C virus (HCV) serine proteases, for example the HCV serine protease NS3. Additionally, compounds disclosed herein can be used to treat viral infections.
- HCV hepatitis C virus
- Treating viral infections can include administering compounds disclosed herein in order to inhibit viral serine proteases (e.g., HCV) or to inhibit mammalian serine proteases necessary for viral infection (e.g., human immunodeficiency virus (HIV); see, e.g., U.S. Pat. No. 6,849,605).
- HCV viral serine proteases
- HAV human immunodeficiency virus
- the compound of the invention can also be administered to treat cardiovascular diseases and other diseases that arise from thrombotic and prothrombotic states in which the coagulation cascade is activated, such as, for example, deep vein thrombosis, disseminated intravascular coagulopathy, Kasabach-Merritt syndrome, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery, and peripheral arterial occlusion.
- cardiovascular diseases and other diseases that arise from thrombotic and prothrombotic states in which the coagulation cascade is activated such as, for example, deep vein thrombosis, disseminated intravascular coagulopathy, Kasabach-Merritt syndrome, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery, and peripheral arterial occlusion.
- a compound of the invention may also be useful in the treatment of adult respiratory distress syndrome, septic shock, septicemia, or inflammatory responses, such as edema and acute or chronic atherosclerosis, because thrombin has been shown to activate a large number of cells outside of the coagulation process, such as, for example, neutrophils, fibroblasts, endothelial cells, and smooth muscle cells.
- the method for treating cardiovascular or related diseases can further comprise concurrent administration of other therapeutic agents already known to be suitable for treating the above-identified diseases.
- methods of the invention include concurrently administering a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention in combination with a therapeutic cardiovascular compound to treat hypertrophy, hypertension, congestive heart failure, heart failure subsequent to myocardial infarction, myocardial ischemia, ischemia reperfusion injury, arrhythmia, or myocardial infarction.
- the cardiovascular disease treated is hypertrophy, congestive heart failure, arrhythmia, or ischemia reperfusion injury.
- the compounds of the invention can also be used in combination with other therapeutic cardiovascular compounds that are generally used to treat cardiovascular or related diseases as well as symptoms thereof.
- a skilled physician or veterinarian readily determines a subject who is exhibiting symptoms of any one or more of the diseases described above and makes the determination about which compound is generally suitable for treating specific cardiovascular conditions and symptoms.
- myocardial ischemia can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent.
- suitable therapeutic agents include, for example, a angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, an antithrombolytic agent, a ⁇ -adrenergic receptor antagonist, a diuretic, an ⁇ -adrenergic receptor antagonist, or a mixture thereof.
- congestive heart failure can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent.
- suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, a vasodilator, a diuretic, or a mixture thereof.
- Myocardial infarction can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent.
- suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, a calcium channel blocker, an antithrombolytic agent, a ⁇ -adrenergic receptor antagonist, a diuretic, an ⁇ -adrenergic receptor antagonist, or a mixture thereof.
- Hypertension can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent.
- suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, a calcium channel blocker, a ⁇ -adrenergic receptor antagonist, a vasodilator, a diuretic, an ⁇ -adrenergic receptor antagonist, or a mixture thereof.
- Arrhythmia can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent.
- suitable therapeutic agents include, for example, a calcium channel blocker, a ⁇ -adrenergic receptor antagonist, or a mixture thereof.
- Blood clots in the arteries (arterial thrombosis) or veins (venous thrombosis) can be reduced or removed by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with an anti-platelet agent such as clopidogrel (aspirin, dipyridamole, etc.), glycoprotein IIb/IIIa inhibitor such as eptifibatide (INTEGRILIN®), or by an anticoagulant such as UFH (unfractionated heparins), LMWH (low molecular weight heparins), hirudin, or argatroban.
- an anti-platelet agent such as clopidogrel (aspirin, dipyridamole, etc.), glycoprotein IIb/IIIa inhibitor such as eptifibatide (INTEGRILIN®)
- an anticoagulant such as UFH (unfractionated heparins), LMWH (low molecular weight heparin
- Hypertrophy can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent.
- suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, or a mixture thereof.
- Ischemia reperfusion injury can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent.
- suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, or a mixture thereof.
- Compounds of the invention or pharmaceutically acceptable salts thereof can be administered post-surgically, alone or concurrently with other suitable therapeutic agents.
- the method would include, but is not limited to, administration to patients following hip replacement surgery, or invasive cardiovascular surgery, including coronary artery bypass graft (CABG), endarectomy, and heart valve replacement.
- Compounds of the invention or pharmaceutically acceptable salts thereof can be administered, alone or concurrently with other suitable therapeutic agents, following any angioplasty procedure.
- administration of said compounds may follow percutaneous transluminal angioplasty (PTA).
- PTA percutaneous transluminal angioplasty
- PTA is used in coronary, pulmonary, peripheral, intracranial, extracranial carotid, renal, and aortic stenoses.
- medical devices can be coated with the compounds of the invention or pharmaceutically acceptable acid salts of the compound alone or in mixture with other suitable therapeutic agents (e.g., an angiotensin converting enzyme inhibitor).
- Medical devices that can be coated with the compounds of the invention or pharmaceutically acceptable salts thereof alone or in mixture with other suitable therapeutic agents include, but are not limited to, intravascular stents and catheters. Intravascular stents are used to prevent blood vessel wall collapse. Drug-eluting stents are coated with a mixture of polymers and drug to prevent restenosis.
- drug-eluting stents examples include the CYPHERTM sirolimus-eluting stent (Cordis Corp., Miami, Fla.) and TAXUSTM paclitaxel-eluting stent (Boston Scientific Corp., Natick, Mass.).
- Hydrogen chloride gas was bubbled into a suspension of 4′-[(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (2) (160 mg, 0.36 mmol) in methyl alcohol (20 mL) at 0° C. for 10 min.
- the solvent was evaporated and the products were purified on a silica gel column using a mixture of methyl alcohol:dichloromethane (1:9) as eluant to give 4′-[(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amino]-biphenyl-2-sulfonic acid amide (3) (139 mg, 25% yield).
- reaction mixture was concentrated and the crude mixture was purified by column chromatography on silica gel using a mixture of methyl alcohol:dichloromethane (1:9) as eluant to give 2′-tert-butylsulfamoyl-biphenyl-4-carboxylic acid (2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-ylmethyl)-amide (4) (196 mg, 67% yield) as a colorless solid.
- reaction mixture was evaporated to dryness, and the crude product was purified by column chromatography on silica gel using a gradient of dichloromethane:methyl alcohol (1:0 to 9:1) as eluant to give 4′- ⁇ [5-(3-cyano-benzyloxy)-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl]-amino ⁇ -biphenyl-2-sulfonic acid tert-butylamide (13) (149 mg, 62% yield) as a colorless solid.
- Hydrogen chloride gas was bubbled into a suspension of 4′- ⁇ [5-(3-cyano-benzyloxy)-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl]-amino ⁇ -biphenyl-2-sulfonic acid tert-butylamide (13) (100 mg, 0.17 mmol) in absolute ethyl alcohol (30 mL) at 0° C. for 30 min. The septum was replaced and the reaction mixture was stirred at room temperature overnight. Hydrogen chloride gas was purged with nitrogen gas for 2 h and the solvent evaporated to give the crude amide ester as a solid.
- This compound was prepared from compound (26) (100 mg, 0.22 mmol) according to the procedure described for Example 3.
- the crude mixture was purified by column chromatography over silica gel using a dichloromethane/methanol (9:1) mixture as eluant. to provide 80 mg, (91%) of (32).
- Platelet rich plasma was obtained by drawing whole blood from normal human donors (not on any medication) into sodium citrate tubes (3.2%), and centrifuging at 160 ⁇ g for about 10 minutes.
- Platelet poor plasma was obtained by centrifuging the remainder of the sample after the platelets were removed at 800 ⁇ g for about 10 minutes.
- the PRP was adjusted to a count of 280 ⁇ 10 9 /L using a mixture of PRP and PPP.
- the platelets 200 ⁇ L
- the samples were incubated for about 3 minutes at about 37° C., and then transferred to the mixing wells of a Chrono-log 4 channel aggregometer (Chrono-log Corp., Havertown, Pa.).
- the agonist 25 ⁇ L of 40 ⁇ M ADP (Sigma, St. Louis, Mo.) or 25 ⁇ L of 50 ⁇ g/mL and 10 ⁇ g/mL collagen (Helena Laboratories, Beaumont, Tex.) or 25 ⁇ L of 120 ⁇ M thrombin receptor activating peptide (TRAP) (Sigma) was then added. Aggregation was monitored for 5 minutes at 37° C. with stirring (1000 rpm).
- the enzymes factor Xa (fXa), thrombin (factor IIa or fIIa), and trypsin were purchased from Haematologic Technologies Inc. (Essex Junction, Vt.).
- the substrates Pefachromes Xa, Th, and Try were purchased from Centerchem Inc. (Stamford, Conn.). Varying concentrations of the sulfonamide compounds were incubated for 30 min at room temperature with purified activated human enzyme in the appropriate buffer. Various concentrations of the corresponding synthetic substrate were added, and activity was measured at 37° C. by monitoring absorbance at 405 nm for 15 min with a Flurostar Optima plate reader.
- Each assay had a final volume of 200 ⁇ L, and assays were performed in 96-well plates.
- 300 ⁇ M of substrate was tested against five concentrations (50, 100, 200, 300, and 500 ⁇ M) of test compound plus control (run in duplicate).
- the appropriate percentage of solvent was used instead of test compound.
- the specific activity ( ⁇ A 405 /min/nM protein), and the percent activity was calculated for each data point.
- the IC 50 was calculated by linear regression of log[test compound] vs. % activity.
- the enzyme activity of the sulfonamide compound was determined using the Enzyme Kinetics Module of Sigmaplot 8.0 (SPSS Inc.)
- the final concentration of human Factor Xa was 2 nM in a Tris/NaCl buffer (pH 7.5) containing 0.25% (w/v) polyethylene glycol (MW 8000).
- the substrate employed was Pefachrome Xa.
- the final concentration of human thrombin was 2 nM in a Tris/NaCl buffer (pH 8.3) containing 0.125% (w/v) bovine serum albumin.
- the substrate used was Pefachrome Th.
- the final concentration of human trypsin was 2 nM in a Tris/NaCl buffer (pH 7.5) containing 0.25% (w/v) bovine serum albumin and 20 ⁇ M CaCl 2 .
- the substrate used was Pefachrome Try.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Materials For Medical Uses (AREA)
Abstract
Aryl sulfonic pyridoxine compounds with inhibition of serine protease activity and antiplatelet aggregation characteristics for the treatment of cardiovascular and cardiovascular related diseases are described. The methods are directed to administering pharmaceutical compositions comprising aryl sulfonic pyridoxines.
Description
- This application is a continuation-in-part of U.S. application Ser. No. 10/974,707, filed Oct. 28, 2004, the entire disclosure of which is hereby incorporated by reference.
- This invention relates to aryl sulfonic pyridoxines and methods of treating cardiovascular, cerebrovascular, and cardiovascular related diseases or symptoms by administering pharmaceutical compositions comprising an aryl sulfonic pyridoxine.
- Thrombosis, the development of blood clots within arterial vessels, is due to a complex mechanism involving the activation of both platelet aggregation and the coagulation protease cascade (Ann. Intern Med. (2001) 134: 224-38; N. Engl. J. Med. (2002) 347: 5-12; Thromb. Haemost. (2002) 86: 51-6). The pathways involved normally inhibit blood loss after vessel injury, but in thrombosis and related conditions, these reactions are inappropriately initiated and propagated.
- On the molecular level, thrombosis is initiated by the release of mediators such as tissue factor (TF), von Willebrand Factor (vWF) (J. Thromb. Haemost. (2003) 1: 1602-1612), and collagen from ruptured atherosclerotic plaques or from damaged blood vessels. Collagen and vWF bind to receptors on platelets and initiate their activation. Once activated, platelets release secretory granules containing ADP, ATP, and calcium (Curr. Opin. Hematol. (2001) δ: 270-276). Activated platelets also synthesize and release thromboxane. The released ADP and thromboxane bind to receptors on the platelets to further propagate platelet activation. Once platelets are activated they start aggregating to initiate clot formation.
- The trypsin-like family of serine proteases play an important role in thrombogenesis (Abbenante & Fairlie (2005) Med. Chem. 1: 71-104; Walenga et al., “Factor Xa Inhibitors” in Anticoagulants, Antiplatelets, and Thrombolytics (Mousa ed.), 93: 95-117 (2004), Humana Press Inc.). Tissue factor (TF), transiently exposed at a vascular site damaged either mechanically or by inflammatory processes, is responsible for initiating the coagulation cascade leading to thrombus formation (Giesen et al. (1999) Proc. Natl. Acad. Sci. USA 96: 2311-2315). Association of TF with activated factor VII (fvIIa) on the membrane surface triggers a complex enzyme amplification network of events that leads to the generation of thrombin and subsequently, conversion of fibrinogen to fibrin. In addition to its role in clot formation, thrombin amplifies its own production and activates platelets via its enzymatic action on platelet protease-activated receptors PAR-1 and PAR-4 (Lane (2005) Blood 106: 2605-2612).
- Since the middle of the last century, anticoagulant therapy has consisted primarily of heparin treatment in acute situations, while vitamin k antagonists have been utilized for chronic therapy. Though these two regimens have proved indispensable in anticoagulant therapy, both approaches have shortcomings which have prompted the development of improved drugs in an attempt to address the limitations of these traditional agents. New approaches involve targeting specific pathways in the coagulation system in order to streamline anticoagulation (Weitz & Bates (2005) J. Thromb. Haemost. 3: 1843-1853). For example, factor Xa (fxa) in the prothrombinase complex generates thrombin (fIIa), and inhibiting either of these enzymes (Yavin et al. (2005) Eur. J. Intern. Med. 16: 257-266), or both Deng, et al. (2005) Bioorg. Med. Chem. Lett. 15: 4411-4416), has been the subject of recent drug design efforts. The notion of dual inhibition in the area of antithrombotics is not new, and in fact unfractionated heparin has several activities including the inhibition of the coagulation pathway serine proteases fIIa and fXa when complexed to antithrombin III.
- Therefore, there is a need for compounds that inhibit the proteases of the blood and thus block platelet aggregation.
- One embodiment of the invention includes aryl sulfonic pyridoxines, compositions containing the aryl sulfonic pyridoxines, and methods of treatment using therapeutically effective amounts of aryl sulfonic pyridoxines. Compounds and compositions of the invention can be used to treat cardiovascular, cerebovascular or related diseases and symptoms thereof.
-
- wherein
- R1 is —OH, —O-alkyl, —(CH2)n′ OH where n′ is an integer from 1 to 8, alkyl, cycloalkyl, or O-alkyl-aryl-R4, where R4 is —CN or amidine;
- R2 is alkyl; —(CH2)n′OH where n′ is as defined above; —(CH2)nCOOH where n is an integer from 0 to 8; —(CH2)nCOO(CH2)nCH3 where n is as defined above; or R5 where R5 is (CH2)n-aryl-R6 where n is as defined above and R6 is SO2NH2 or SO2NHC(CH3)3; (CH2)n-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-aryl-R6, where n and R6 are as defined above; or —(CH2)n—NH-aryl-R6, where n and R6 are as defined above;
- R3 is alkyl; —(CH2)n′OH where n′ is as defined above; or R5 where R5 is (CH2)n—NH-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-R6 where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6 where n and R6 are as defined above; or (CH2)n—NH—CO-aryl-aryl-R6 where n and R6 are as defined above;
- further wherein
-
- R2 is alkyl or —(CH2)n′OH where n′ is as defined above, and R3 is R5; or
- R2 is R5 and R3 is alkyl or —(CH2)n′OH where n′ is as defined above; and
-
-
- wherein
- R1 is —OH, —O-alkyl, —(CH2)n′ OH where n′ is an integer from 1 to 8, alkyl, cycloalkyl, or O-alkyl-aryl-R4, where R4 is —CN or amidine;
- R2 is alkyl; —(CH2)n′OH where n′ is as defined above; —(CH2)n′ COOH where n is an integer from 0 to 8; —(CH2)nCOO(CH2)nCH3 where n is as defined above; or R5 where R5 is (CH2)n-aryl-R6 where n is as defined above and R6 is SO2NH2 or SO2NHC(CH3)3; (CH2)n-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-aryl-R6, where n and R6 are as defined above; or —(CH2)n—NH-aryl-aryl-R6 where n and R6 are as defined above;
- R3 is alkyl; —(CH2)n′OH where n′ is as defined above; or R5 where R5 is (CH2)n—NH-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-R6 where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6 where n and R6 are as defined above; or (CH2)n—NH—CO-aryl-aryl-R6 where n and R6 are as defined above;
- further wherein
-
- R2 is alkyl or —(CH2)n′ OH where n′ is as defined above, and R3 is R5; or
- R2 is R5 and R3 is alkyl or —(CH2)n′ OH where n′ is as defined above; and
-
- wherein R7 and R8 are independently H or CH3, and R5 is as defined above;
- or a pharmaceutically acceptable salt thereof.
-
- wherein
-
-
-
- where W is (CH2)n where n=1, 2, or 3; where X is C=0 or (CH2)n′, where n′=0, 1, 2, or
- 3; Y is CH, CF, or N; and R6 is
- R3 is (CH2)mOH, where m is as defined above; or R5, where R5 is as defined above;
- further wherein
-
- R2 is (CH2)mOH, where m is as defined above, and R3 is R5; or
- R2 is R5 and R3 is (CH2)mOH, where m is as defined above; and
-
- wherein R7 and R8 are independently H or CH3; and R5 is as defined above;
- or a pharmaceutically acceptable salt thereof.
- As used herein “alkyl” includes a saturated linear or branched hydrocarbon radical. In one embodiment, alkyl has from 1 to 8 carbon atoms. In another embodiment, alkyl has from 1 to 6 carbon atoms. In another embodiment, alkyl has from 1 to 4 carbon atoms. In one embodiment, alkyl has 1 carbon. The alkyl group may optionally be substituted with one or more substituents such as fluorine, chlorine, alkoxy groups having from 1 to 8 carbon atoms (e.g., methoxy or ethoxy), or amido groups having from 1 to 8 carbon atoms, such as acetamido. These substituents may themselves be substituted with one or more functional groups such as hydroxy groups, carboxy groups, acetoxy groups, or halogens.
- As used herein “cycloalkyl” refers to a cyclic hydrocarbon having from 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, such as, for example, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
- As used herein “aryl” means a mono- or poly-nuclear aromatic hydrocarbon radical. Examples of “aryl” groups include, but are not limited to aromatic hydrocarbons such as a phenyl group or a naphthyl group. The aromatic group may optionally be substituted with one or more substituents such as fluorine, chlorine, alkyl groups having from 1 to 10 carbon atoms (e.g., methyl or ethyl), alkoxy groups having from 1 to 8 carbon atoms (e.g., methoxy or ethoxy), alkoxyalkyl groups having from 1 to 8 carbon atoms and one or more oxygen atoms, or amido groups having from 1 to 8 carbon atoms, such as acetamido. These substituents may themselves be substituted with one or more functional groups such as hydroxy groups, carboxy groups, acetoxy groups, or halogens.
- In one embodiment, aryl is a phenyl group or a naphthyl group that is either unsubstituted or substituted.
- In another embodiment, aryl is a heteroaryl in which one or more of the carbon atoms of an aromatic hydrocarbon is substituted with a nitrogen, sulfur, or oxygen. Examples of a “heteroaryl” include, but are not limited to pyridine, pyrimidine, pyran, dioxin, oxazine, and oxathiazine. Likewise, the heteroaryl may optionally be substituted with functional groups such as hydroxy groups, carboxy groups, halogens, and amino groups.
-
- The invention also includes pharmaceutically acceptable salts of the compounds of the invention. The compounds of the invention are capable of forming both pharmaceutically acceptable acid addition and/or base salts. Pharmaceutically acceptable acid addition salts of the compounds of the invention include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and di-carboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine, etc. (see Berge et al., J. Pharmaceutical Science, 66: 1-19 (1977). The term “pharmaceutically acceptable salts” also includes any pharmaceutically acceptable base salt including, but not limited to, amine salts, trialkyl amine salts and the like. Such salts can be formed quite readily by those skilled in the art using standard techniques.
- The acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention. Base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations include, but are not limited to, sodium, potassium, magnesium, and calcium. Examples of suitable amines are N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.
- Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)- . The present invention is meant to include all such possible diastereomers and enantiomers as well as their racemic and optically pure forms. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise all tautomeric forms are intended to be included.
- General Methods of Preparing Compounds of Formulae I, II, III, and IV
- The compounds are generally prepared by combining an aldehyde or a carboxylate with an amine group to produce an elaborated pyridine structure. The general scheme of preparing the compounds of the formulae comprise protecting the hydroxyl groups at R1 and R2 of pyridoxine with known blocking groups such as esters, ethers, cyclic acetals, cyclic ketals, etc. and elaborating R3 through generating an aldehyde, acid, halide, or amine functionality as shown in Schemes 1-4. R3 may be an aryl or biaryl containing a nitro, amino, or cyano group that can be converted to an amidine by known chemical procedures. Additionally, protecting R1 and R3 with known blocking groups such as esters, ethers, cyclic acetals, cyclic ketals, etc. and elaborating R2 through generating an aldehyde, acid, halide, or amine functionality can be achieved through the same general scheme as shown in Scheme 5.
where the dashed lines are (CH2)n where n=0-8.
where the dashed lines are (CH2)n and n=0-8.
where the dashed lines are (CH2)n and n=0-8.
where the dashed lines are (CH2)n and n=0-8.
where R3 is (CH2)n—Ar—X, where n=0-8 and Ar—X is any aromatic terminating in —SO2NH2 or —SO2NH2C(CH3)3. - Other positions on the pyridoxine ring can also be substituted according to the aforementioned general scheme. Substitutions are not specific to the positions described above.
- Conditions to Be Treated
- In one embodiment of the invention, compounds of the invention can be used to treat cardiovascular or related diseases. Cardiovascular or related diseases include, for example, cerebral ischemia, cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, hypertension, myocardial infarction, ischemia reperfusion injury, myocardial ischemia, congestive heart failure, blood coagulation disorders, cardiac hypertrophy, and platelet aggregation. Cardiovascular or related diseases also include diseases that arise from thrombotic and prothrombotic states in which the coagulation cascade is activated such as, for example, deep vein thrombosis, disseminated intravascular coagulopathy, and pulmonary embolism.
- Heart failure is a pathophysiological condition in which the heart is unable to pump blood at a rate commensurate with the requirement of the metabolizing tissues or can do so only from an elevated filling pressure (increased load). Thus, the heart has a diminished ability to keep up with its workload. Over time, this condition leads to excess fluid accumulation, such as peripheral edema, and is referred to as congestive heart failure.
- When an excessive pressure or volume load is imposed on a ventricle, myocardial hypertrophy (i.e., enlargement of the heart muscle) develops as a compensatory mechanism. Hypertrophy permits the ventricle to sustain an increased load because the heart muscle can contract with greater force. However, a ventricle subjected to an abnormally elevated load for a prolonged period eventually fails to sustain an increased load despite the presence of ventricular hypertrophy, and pump failure can ultimately occur.
- Heart failure can arise from any disease that affects the heart and interferes with circulation. For example, a disease that increases the heart muscle's workload, such as hypertension, will eventually weaken the force of the heart's contraction. Hypertension is a condition in which there is an increase in resistance to blood flow through the vascular system. This resistance leads to increases in systolic pressure, diastolic blood pressure, or both. Hypertension places increased tension on the left ventricular myocardium, causing it to stiffen and hypertrophy, and accelerates the development of atherosclerosis in the coronary arteries. The combination of increased demand and lessened supply increases the likelihood of myocardial ischemia leading to myocardial infarction, sudden death, arrhythmias, and congestive heart failure.
- Ischemia is a condition in which an organ or a part of the body fails to receive a sufficient blood supply. When an organ is deprived of a blood supply, it is said to be hypoxic. An organ will become hypoxic even when the blood supply temporarily ceases, such as during a surgical procedure or during temporary artery blockage. Ischemia initially leads to a decrease in or loss of contractile activity. When the organ effected is the heart, this condition is known as myocardial ischemia, and myocardial ischemia initially leads to abnormal electrical activity. This can generate an arrhythmia. When myocardial ischemia is of sufficient severity and duration, cell injury can progress to cell death—i.e., myocardial infarction—and subsequently to heart failure, hypertrophy, or congestive heart failure.
- Ischemic reperfusion of the organ occurs when blood flow resumes to an organ after temporary cessation. For example, reperfusion of an ischemic myocardium can counter the effects of coronary occlusion, a condition that leads to myocardial ischemia. Ischemic reperfusion to the myocardium can lead to reperfusion arrhythmia or reperfusion injury. The severity of reperfusion injury is affected by numerous factors, such as, for example, duration of ischemia, severity of ischemia, and speed of reperfusion. Conditions observed with ischemia reperfusion injury include neutrophil infiltration, necrosis, and apoptosis.
- Pharmaceutical Compositions
- Although it is possible for compounds of the invention to be administered alone in a unit dosage form, the compounds are typically administered in admixture with a carrier as a pharmaceutical composition to provide a unit dosage form. The invention provides pharmaceutical compositions containing at least one compound of the invention. A pharmaceutical composition comprises a pharmaceutically acceptable carrier in combination with a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
- A pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate-buffered saline, and other carriers known in the art. Pharmaceutical compositions can also include additives such as, for example, stabilizers, antioxidants, colorants, excipients, binders, thickeners, dispersing agents, readsorpotion enhancers, buffers, surfactants, preservatives, emulsifiers, isotonizing agents, and diluents. Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.
- Methods of preparing pharmaceutical compositions containing a pharmaceutically acceptable carrier in combination with a therapeutic compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention are known to those of skill in the art. All methods can include the step of bringing the compound of the invention in association with the carrier and additives. The formulations generally are prepared by uniformly and intimately bringing the compound of the invention into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage forms.
- For oral administration as a tablet or capsule, the compositions can be prepared according to techniques well known in the art of pharmaceutical formulation. The compositions can contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents. As immediate release tablets, the compositions can contain microcrystalline cellulose, starch, magnesium stearate and lactose or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
- For administration by inhalation or aerosol, the compositions can be prepared according to techniques well known in the art of pharmaceutical formulation. The compositions can be prepared as solutions in saline, using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons or other solubilizing or dispersing agents known in the art.
- For administration as injectable solutions or suspensions, the compositions can be formulated according to techniques well-known in the art, using suitable dispersing or wetting and suspending agents, such as sterile oils, including synthetic mono- or di-glycerides, and fatty acids, including oleic acid.
- For rectal administration as suppositories, the compositions can be prepared by mixing with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ambient temperatures, but liquefy or dissolve in the rectal cavity to release the drug.
- Method of Treatment Using Compounds of the Invention
- In another aspect of the invention, methods are provided for the treatment of cardiovascular or related diseases and symptoms thereof.
- As used herein, the terms “treatment” and “treating” include inhibiting, alleviating, and healing cardiovascular or related diseases or symptoms thereof. Treatment can be carried out by administering a therapeutically effective amount of at least one compound of the invention. A “therapeutically effective amount” as used herein includes a prophylactic amount, for example an amount effective for alleviating or healing the above mentioned diseases or symptoms thereof.
- A physician or veterinarian of ordinary skill readily determines a mammalian subject who is exhibiting symptoms of any one or more of the diseases described above. Regardless of the route of administration selected, a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention can be formulated into pharmaceutically acceptable unit dosage forms by conventional methods known in the pharmaceutical art. An effective but nontoxic quantity of the compound is employed in treatment. The compounds can be administered in enteral unit dosage forms, such as, for example, tablets, sustained-release tablets, enteric coated tablets, capsules, sustained-release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like. They can also be administered parenterally, such as, for example, subcutaneously, intramuscularly, intradermally, intramammarally, intravenously, and by other administrative methods known in the art.
- The ordinarily skilled physician or veterinarian will readily determine and prescribe the therapeutically effective amount of the compound to treat the disease for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained. Typically, the particular disease, the severity of the disease, the compound to be administered, the route of administration, and the characteristics of the mammal to be treated, for example, age, sex, and weight, are considered in determining the effective amount to administer. Administering a therapeutic amount of a compound of the invention for treating cardiovascular or related diseases or symptoms thereof, is in a range of about 0.1-100 mg/kg of a patient's body weight, more preferably in the range of about 0.5-50 mg/kg of a patient's body weight, per daily dose. The compound can be administered for periods of short and long duration. Although some individual situations can warrant to the contrary, short-term administration, for example, 30 days or less, of doses larger than 25 mg/kg of a patient's body weight is preferred to long-term administration. When long-term administration, for example, months or years, is required, the suggested dose usually does not exceed 25 mg/kg of a patient's body weight.
- A therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable addition salt of a compound of the invention for treating the above-identified diseases or symptoms thereof can be administered prior to, concurrently with, or after the onset of the disease or symptom. A compound of the invention can be administered concurrently. “Concurrent administration” and “concurrently administering” as used herein includes administering a compound of the invention and another therapeutic agent in admixture, such as, for example, in a pharmaceutical composition or in solution, or separately, such as, for example, separate pharmaceutical compositions or solutions administered consecutively, simultaneously, or at different times but not so distant in time such that the compound of the invention and the other therapeutic agent cannot interact and a lower dosage amount of the active ingredient cannot be administered.
- In one embodiment of the invention, a method is provided for treating cardiovascular or related diseases comprising administering to a mammal a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable addition salt of a compound of the invention in a unit dosage form. The cardiovascular or related diseases that can be treated include hypertrophy, hypertension, congestive heart failure, heart failure subsequent to myocardial infarction, myocardial ischemia, cerebral ischemia, ischemia reperfusion injury, arrhythmia, myocardial infarction, blood coagulation, platelet aggregation, atherosclerosis, atrial fibrillation, or acute coronary syndrome. Preferably, the cardiovascular disease treated is hypertrophy, congestive heart failure, arrhythmia, or ischemia reperfusion injury. Compounds of the invention may also be administered as anticoagulants to patients with heparin induced thrombocyotpenia (HIT).
- Serine protease activity can be inhibited by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention. Compounds of the invention can be administered to inhibit serine protease activity in a mammal, thereby affecting varying disease states, including platelet aggregation. Compounds of the invention can inhibit serine proteases such as, but not limited to, trypsin, chymotrypsin, kallikrein, elastase, thrombin (Factor IIa), plasmin, Factors VIIa, IXa, Xa, XIa, XIIa, and protein C. Preferably, the mammal is a human. Compounds of the invention can also be used to inhibit serine protease activity in vitro. Serine protease inhibitors can be useful for research and diagnostic purposes. For instance, compounds of the invention can inhibit serine protease activity in a monolayer of a cell culture following contact with the cells of said cell culture.
- In another embodiment, compounds of the invention can be administered to inhibit non-mammalian serine proteases. The non-mammalian serine protease can be from microorganisms, including bacteria and viruses. Bacterial serine proteases include, but is not limited to, subtilisin (from Bacillus subtilis). Viral serine proteases can be inhibitied by compounds disclosed herein, including, but not limited to, hepatitis C virus (HCV) serine proteases, for example the HCV serine protease NS3. Additionally, compounds disclosed herein can be used to treat viral infections. Treating viral infections can include administering compounds disclosed herein in order to inhibit viral serine proteases (e.g., HCV) or to inhibit mammalian serine proteases necessary for viral infection (e.g., human immunodeficiency virus (HIV); see, e.g., U.S. Pat. No. 6,849,605).
- The compound of the invention can also be administered to treat cardiovascular diseases and other diseases that arise from thrombotic and prothrombotic states in which the coagulation cascade is activated, such as, for example, deep vein thrombosis, disseminated intravascular coagulopathy, Kasabach-Merritt syndrome, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery, and peripheral arterial occlusion. A compound of the invention may also be useful in the treatment of adult respiratory distress syndrome, septic shock, septicemia, or inflammatory responses, such as edema and acute or chronic atherosclerosis, because thrombin has been shown to activate a large number of cells outside of the coagulation process, such as, for example, neutrophils, fibroblasts, endothelial cells, and smooth muscle cells.
- The method for treating cardiovascular or related diseases can further comprise concurrent administration of other therapeutic agents already known to be suitable for treating the above-identified diseases. For example, methods of the invention include concurrently administering a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention in combination with a therapeutic cardiovascular compound to treat hypertrophy, hypertension, congestive heart failure, heart failure subsequent to myocardial infarction, myocardial ischemia, ischemia reperfusion injury, arrhythmia, or myocardial infarction. Preferably, the cardiovascular disease treated is hypertrophy, congestive heart failure, arrhythmia, or ischemia reperfusion injury.
- The compounds of the invention can also be used in combination with other therapeutic cardiovascular compounds that are generally used to treat cardiovascular or related diseases as well as symptoms thereof. A skilled physician or veterinarian readily determines a subject who is exhibiting symptoms of any one or more of the diseases described above and makes the determination about which compound is generally suitable for treating specific cardiovascular conditions and symptoms.
- For example, myocardial ischemia can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent. Other suitable therapeutic agents include, for example, a angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, an antithrombolytic agent, a β-adrenergic receptor antagonist, a diuretic, an α-adrenergic receptor antagonist, or a mixture thereof.
- As another example, congestive heart failure can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent. Other suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, a vasodilator, a diuretic, or a mixture thereof.
- Myocardial infarction can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent. Other suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, a calcium channel blocker, an antithrombolytic agent, a β-adrenergic receptor antagonist, a diuretic, an α-adrenergic receptor antagonist, or a mixture thereof.
- Hypertension can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent. Other suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, a calcium channel blocker, a β-adrenergic receptor antagonist, a vasodilator, a diuretic, an α-adrenergic receptor antagonist, or a mixture thereof.
- Arrhythmia can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent. Other suitable therapeutic agents include, for example, a calcium channel blocker, a β-adrenergic receptor antagonist, or a mixture thereof.
- Blood clots in the arteries (arterial thrombosis) or veins (venous thrombosis) can be reduced or removed by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with an anti-platelet agent such as clopidogrel (aspirin, dipyridamole, etc.), glycoprotein IIb/IIIa inhibitor such as eptifibatide (INTEGRILIN®), or by an anticoagulant such as UFH (unfractionated heparins), LMWH (low molecular weight heparins), hirudin, or argatroban.
- Hypertrophy can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent. Other suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, or a mixture thereof.
- Ischemia reperfusion injury can be treated by the administration of a compound of the invention or a pharmaceutically acceptable acid addition salt of a compound of the invention concurrently with another therapeutic agent. Other suitable therapeutic agents include, for example, an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, or a mixture thereof.
- Compounds of the invention or pharmaceutically acceptable salts thereof can be administered post-surgically, alone or concurrently with other suitable therapeutic agents. For instance, the method would include, but is not limited to, administration to patients following hip replacement surgery, or invasive cardiovascular surgery, including coronary artery bypass graft (CABG), endarectomy, and heart valve replacement. Compounds of the invention or pharmaceutically acceptable salts thereof can be administered, alone or concurrently with other suitable therapeutic agents, following any angioplasty procedure. For instance, administration of said compounds may follow percutaneous transluminal angioplasty (PTA). PTA is used in coronary, pulmonary, peripheral, intracranial, extracranial carotid, renal, and aortic stenoses.
- Additionally, medical devices can be coated with the compounds of the invention or pharmaceutically acceptable acid salts of the compound alone or in mixture with other suitable therapeutic agents (e.g., an angiotensin converting enzyme inhibitor). Medical devices that can be coated with the compounds of the invention or pharmaceutically acceptable salts thereof alone or in mixture with other suitable therapeutic agents include, but are not limited to, intravascular stents and catheters. Intravascular stents are used to prevent blood vessel wall collapse. Drug-eluting stents are coated with a mixture of polymers and drug to prevent restenosis. Examples of drug-eluting stents are the CYPHER™ sirolimus-eluting stent (Cordis Corp., Miami, Fla.) and TAXUS™ paclitaxel-eluting stent (Boston Scientific Corp., Natick, Mass.).
- This invention is further characterized by the following examples. These examples are not meant to limit the scope of the invention but are provided for exemplary purposes to more fully describe the invention. Variation within the scope of the invention will be apparent to those skilled in the art.
- All reagents used were purchased from standard commercial sources, or synthesized by known literature methods. HPLC analysis was performed using a Waters 996 PDA high performance liquid chromatograph equipped with a Waters 600 controller. Signals were detected with a photodiode array detector (set at max plot 254-400 nm). NMR spectra were recorded on a Bruker AM-300 instrument (13C, 19F and 31P at 75.5, 282 and 121 MHz respectively) and were calibrated using residual nondeuterated solvent as the internal reference. All 19F spectra are reported using hexafluorobenzene (δ −162.9 ppm) as the external standard while 31p spectra were collected using 85% H3PO4 (δ0.0 ppm) as the external reference.
-
- To a 250 mL three neck flask fitted with a condenser and Dean-Stark apparatus was added 4′-amino-biphenyl-2-sulfonic acid tert-butylamide (1.22 g, 4.0 mmol), p-toluenesulfonic acid monohydrate (152 mg, 0.8 mmol), 2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridine-5-carbaldehyde (995 mg, 4.8 mmol, see Korytnyk et al., Methods Enzymol. 1970; 18A: 524-566) and toluene (120 ml). The reaction mixture was stirred at 120° C. under nitrogen atmosphere for 7 h before concentrating to dryness. The resulting solid was then dissolved in acetic acid (20 mL), cooled to 0° C., and sodium borohydride (529 mg, 14 mmol) was added slowly. After the addition of sodium borohydride was complete, dichloromethane (30 mL) was added to the reaction mixture and stirring was continued at room temperature for an additional 3 h. Sodium hydroxide (5 N) was added to neutralize the solution, and the reaction mixture was extracted with ethyl acetate, dried over MgSO4, filtered and evaporated. The crude mixture was purified by column chromatography on silica gel using a mixture of ethyl acetate and hexane (1:1) as eluant, to give 4′-[(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (1) (0.457 g, 24% yield) as a colorless solid.
- 1H-NMR (CDCl3): δ 8.13 (d, 1H), 8.04 (s, 1H), 7.52 (t, 1H), 7.41 (t, 1H), 7.35 (d, 2H), 7.28 (d, 1H), 6.70 (d, 2H), 4.90 (s, 2H), 4.20 (d, 2H), 3.99 (t, 1H), 3.69 (s, 1H), 2.41(s, 3H), 1.56 (s, 6H), 0.98 (s, 9H).
-
- To a solution of 10% formic acid in water (50 mL) was added 3-[(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-ylmethyl)-amino]-benzonitrile (1) (336 mg, 0.7 mmol) and the reaction mixture was heated at 100° C. under nitrogen atmosphere. The reaction mixture was then concentrated to dryness. The resulting pale yellow solid was dissolved in small amount of dichloromethane and diethyl ether was added to induce precipitation of a yellow solid. The pale yellow 4′-[(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (2) (215 mg, 70% yield) was collected by filtration.
- 1H-NMR (DMSO-d6): δ 8.70 (s, 1H), 8.07 (d, 1H), 7.77 (s, 1H), 7.60 (m, 2H), 7.43 (s, 4H), 7.33 (d, 1H), 5.14 (s, 2H), 4.77 (s, 2H), 2.33 (s, 3H), 0.98 (s, 9H).
-
- Hydrogen chloride gas was bubbled into a suspension of 4′-[(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (2) (160 mg, 0.36 mmol) in methyl alcohol (20 mL) at 0° C. for 10 min. The solvent was evaporated and the products were purified on a silica gel column using a mixture of methyl alcohol:dichloromethane (1:9) as eluant to give 4′-[(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amino]-biphenyl-2-sulfonic acid amide (3) (139 mg, 25% yield).
- 1H-NMR (CD3OD): δ 8.08 (d, 1H), 7.92 (s, 1H), 7.59 (t, 1H), 7.47 (t, 1H), 7.33 (d, 1H), 7.24 (d, 2H), 6.74 (d, 2H), 4.99 (s, 2H), 4.36 (s, 2H), 2.43 (s, 3H). MS m/z (ES+): 400.22 (M+H+).
-
- A mixture of 2′-tert-butylsulfamoyl-biphenyl-4-carboxylic acid mono-sodium salt (200 mg, 0.56 mmol), 2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)-methylamine (123 mg, 0.59 mmol), 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) (226 mg, 1.18 mmol), and 4-(dimethylamino)pyridine (DMAP) (144 mg, 1.18 mmol) in anhydrous dichloromethane (25 mL) was stirred at room temperature under nitrogen atmosphere overnight. The reaction mixture was concentrated and the crude mixture was purified by column chromatography on silica gel using a mixture of methyl alcohol:dichloromethane (1:9) as eluant to give 2′-tert-butylsulfamoyl-biphenyl-4-carboxylic acid (2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-ylmethyl)-amide (4) (196 mg, 67% yield) as a colorless solid.
- 1H-NMR (CDCl3): δ 8.16 (s, 1H), 8.04 (d, 1H), 7.94 (d, 2H), 7.57-7.46 (m, 5H), 5.01(s, 2H), 4.58 (d, 2H), 4.03 (s, 1H), 2.50 (s, 3H), 1.56 (s, 6H), 1.01 (s, 9H).
-
- The hydrolysis of 2′-tert-butylsulfamoyl-biphenyl-4-carboxylic acid (2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-ylmethyl)-amide (4) (300 mg, 0.57 mmol), following the procedure described in Example 2, gave 2′-tert-butylsulfamoyl-biphenyl-4-carboxylic acid (5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amide (5) (219 mg, 79% yield) as a colorless solid.
- 1H-NMR (CD3OD): δ 8.32 (m, 4H), 8.16 (s, 1H), 8.09 (d, 2H), 7.84 (t, 1H), 7.75 (d, 3H), 7.54 (d, 1H), 5.23 (s, 2H), 4.84 (s, 2H), 2.66 (s, 3H), 1.25 (s, 9H). MS m/z (ES+): 484.41 (M+H+).
-
- The hydrolysis of 2′-tert-butylsulfamoyl-biphenyl-4-carboxylic acid (5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amide (5) (101 mg, 0.21 mmol), following the procedure described in Example 3, gave 2′-sulfamoyl-biphenyl-4-carboxylic acid (5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amide (6) (219 mg, 79% yield) as a colorless solid.
- 1H-NMR (CD3OD): δ 8.27 (m, 2H), 8.05 (d, 2H), 7.81-7.72 (m, 2H), 7.68 (d, 2H), 7.48 (d, 1H), 5.35 (s, 2H), 4.85 (s, 2H), 2.78 (s, 3H). MS m/z (ES+): 428.29 (M+H+).
-
- A mixture of pyridoxal hydrochloride (330 mg, 1.62 mmol), 4′-amino-biphenyl-2-sulfonic acid tert-butylamide (494 mg, 1.62 mmol), p-toluenesulfonic acid monohydrate (68 mg, 0.36 mmol) and toluene (150 mL) was added to a 250 mL three-necked round bottom flask fitted with a condenser and a Dean-Stark trap, and heated at 100° C. under nitrogen atmosphere for 3 h. The solvent was then evaporated and the crude product was dissolved in dichloromethane (70 mL), cooled down to 0° C. and then sodium borohydride (163 mg, 4.32 mmol) and methyl alcohol (15 mL) were added. The reaction mixture was stirred at room temperature overnight, after which time the solvent was removed. The residue was diluted with saturated aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The crude product was purified by column chromatography on silica gel using a mixture of dichloromethane:methyl alcohol (9:1) as eluant to give 4′-[(3-hydroxy-5-hydroxymethyl-2-methyl-pyridin-4-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (7) (178 mg, 24% overall yield for two steps) as a colorless solid.
- 1H-NMR (CDCl3): δ 8.13 (dd, 1H), 7.84 (s, 1H), 7.53 (td, 1H), 7.44 (td, 1H), 7.37 (d, 2H), 7.27 (dd, 1H), 6.89 (d, 2H), 4.68 (s, 2H), 4.61 (s, 2H), 3.71 (s, 1H), 2.44 (s, 3H), 0.98 (s, 9H). MS m/z (ES+): 456.29 (M+H+).
-
- The hydrolysis of 4′-[(3-hydroxy-5-hydroxymethyl-2-methyl-pyridin-4-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (7) (75 mg, 0.16 mmol), following the procedure described in Example 3, gave 4′-[(3-hydroxy-5-hydroxymethyl-pyridin-4-ylmethyl)-amino]-biphenyl-2-sulfonic acid amide (8) (49 mg, 76% yield) as a colorless solid.
- 1H-NMR (CD3OD): δ 8.09 (s, 1H), 7.92 (dd, 1H), 7.45-7.38 (m, 2H), 7.28 (dt, 2H), 7.16-7.10 (m, 3H), 4.70 (s, 2H), 4.66 (s, 2H), 2.53 (s, 3H). MS m/z (ES+): 400.28 (M+H+).
-
- The reductive amination of pyridoxal hydrochloride (436.4 mg, 2.143 mmol) and 4′-amino-3′-fluoro-biphenyl-2-sulfonic acid tert-butylamide (760 mg, 2.357 mmol), following the procedure described in Example 7, gave 3′-fluoro-4′-[(3-hydroxy-5-hydroxymethyl-2-methyl-pyridin-4-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (9).
- 1H-NMR (CD3OD): δ 8.06 (d, 1H), 7.9 (br s, 1H), 7.57 (t, 1H), 7.47 (t, 1H), 7.3 (d, 1H), 7.1 (dd, 1H), 7.07 (d, 1H), 7.01 (t, 1H), 4.75 (s, 2H), 4.61 (s, 2H), 0.98 (s, 9H). 9F-NMR (CD3OD; 1H-decoupled): δ −135.5.
-
- Compound (10) was prepared according to the procedure described in Example 1 from 2-amino-5-bromopyridine (4.33 g, 25 mmol) and 2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridine-5-carbaldehyde (5.18 g, 25 mmol). The crude mixture was purified by column chromatography over silica gel using a hexane/ethyl acetate (1:1) mixture as eluant to furnish 1.8 g (20%) of (10).
- 1H-NMR CD3OD): δ 7.99 (d, 1H), 7.89 (s, 1H), 7.5 (dd, 1H), 6.5 (d, 1H), 4.95 (s, 2H), 4.37 (s, 2H), 2.33 (s, 3H), 1.56 (s, 6H).
-
- A mixture of (5-bromo-pyridin-2-yl)-(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)-amine (10) (564 mg, 1.55 mmol), tetrakis(triphenylphosphine) palladium(0) (174 mg, 0.15 mmol), cesium carbonate (1.56 g, 4.8 mmol), 2-tert-butylsulfamoyl-phenylboronic acid (438 mg, 1.7 mmol) in a solution of toluene (20 mL), iso-butyl alcohol (15 mL) and water (5 mL) was stirred at 80° C. under nitrogen for 5 h. The reaction was diluted with water and extracted with ethyl ether. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The crude product was purified by column chromatography on silica gel to give N-tert-butyl-2-[6-(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-ylamino)-pyridin-3-yl]-benzenesulfonamide (11) as a colorless solid (554 mg, 74% yield).
- 1H-NMR (CDCl3): δ 8.15 (d, 1H), 8.10 (s, 1H), 8.03 (s, 1H), 7.68 (d, 1H), 7.55 (t, 1H), 7.46 (t, 1H), 7.27 (d, 1H), 6.47 (d, 1H), 4.91 (s, 2H), 4.84 (t, 1H), 4.44 (d, 2H), 3.76 (s, 1H), 2.40 (s, 3H), 1.55 (s, 6H), 1.03 (s, 9H).
-
- The hydrolysis of N-tert-butyl-2-[6-(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyrdin-5-ylamino)-pyridin-3-yl]-benzenesulfonamide (12) (305 mg, 0.63 mmol), following the procedure described in Example 2, gave N-tert-butyl-2-[6-(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-benzenesulfonamide (12) (244 mg, 84% yield) as a colorless solid.
- 1H-NMR (CD3OD): δ 8.13-8.10 (m, 3H), 7.97 (d, 2H), 7.64-7.60 (m, 2H), 7.52 (t, 1H), 7.34 (d, 1H), 6.69 (d, 1H), 5.02 (s, 2H), 4.59 (s, 2H), 2.46 (s, 3H), 1.06 (s, 9H).
-
- A mixture of 4′-[(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (2) (190 mg, 0.42 mmol), α-bromo-m-tolunitrile (90 mg, 0.46 mmol) and potassium carbonate (177 mg, 1.28 mmol) in DMF (10 mL) were stirred at room temperature under nitrogen atmosphere overnight. The reaction mixture was evaporated to dryness, and the crude product was purified by column chromatography on silica gel using a gradient of dichloromethane:methyl alcohol (1:0 to 9:1) as eluant to give 4′-{[5-(3-cyano-benzyloxy)-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl]-amino}-biphenyl-2-sulfonic acid tert-butylamide (13) (149 mg, 62% yield) as a colorless solid.
- 1H-NMR (CDCl3): δ 8.39 (s, 1H), 8.16 (d, 1H), 7.83 (s, 1H), 7.75-7.68 (m, 2H), 7.59-7.53 (m, 2H), 7.49-7.41 (m, 3H), 7.31 (d, 2H), 6.87 (d, 2H), 5.03 (s, 2H), 4.81 (s, 2H), 4.46 (s, 2H), 3.70 (s, 1H), 2.58 (s, 3H), 1.02 (s, 9H).
-
- Hydrogen chloride gas was bubbled into a suspension of 4′-{[5-(3-cyano-benzyloxy)-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl]-amino}-biphenyl-2-sulfonic acid tert-butylamide (13) (100 mg, 0.17 mmol) in absolute ethyl alcohol (30 mL) at 0° C. for 30 min. The septum was replaced and the reaction mixture was stirred at room temperature overnight. Hydrogen chloride gas was purged with nitrogen gas for 2 h and the solvent evaporated to give the crude amide ester as a solid. Ammonia in methyl alcohol (30 mL, 7 M, 350 mmol) was added to the crude amide ester and the reaction mixture was stirred overnight at room temperature. The solvent was evaporated and the product purified on a silica gel column using a mixture of dichloromethane:methyl alcohol (4:1) as eluant to give the corresponding 3-{4-hydroxymethyl-5-[(2′-sulfamoyl-biphenyl-4-ylamino)-methyl]-pyridin-3-yloxymethyl}-benzamidine (14) (90 mg, 97% yield) as a colorless powder.
- 1H-NMR (CD3OD): δ 8.30 (s, 1H), 8.07 (d, 1H), 8.01 (s, 1H), 7.92 (d, 1H), 7.84 (d, 1H), 7.70 (t, 1H) 7.58 (t, 1H), 7.46 (t, 1H), 7.32 (d, 1H), 7.24 (d, 2H), 6.77 (d, 2H), 5.11 (s, 2H), 4.58 (s, 2H), 3.36 (s, 2H), 2.52 (s, 3H). MS m/z (ES+): 532.37 (M+H+).
-
- The coupling of N-tert-butyl-2-[6-(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-benzenesulfonamide (12) (205 mg, 0.45 mmol) and α-bromo-m-tolunitrile (88 mg, 0.45 mmol), following the procedure described in Example 13, gave N-tert-butyl-2-{6-[3-(3-cyano-benzyloxy)-2-hydroxymethyl-4-methyl-benzylamino]-pyridin-3-yl}3-benzenesulfonamide (15) (23 mg, 9% yield).
- 1H-NMR (CDCl3): δ 8.38 (s, 1H), 8.14 (dd, 1H), 7.98 (d, 1H), 7.81 (s, 1H), 7.74-7.64 (m, 3H), 7.55-7.46 (m, 3H), 7.24 (dd, 1H), 6.56 (d, 1H), 5.35 (t, 1H), 4.99 (s, 2H), 4.85 (s, 2H), 4.71 (d, 2H), 3.63 (s, 1H), 2.51 (s, 3H), 1.00 (s, 9H).
-
- The conversion of nitrile (15) to amidine (16) was carried out as described in Example 14.
- 1H-NMR (CD3OD): δ 8.32 (s, 1H), 8.11 (dd, 1H), 8.01 (t, 1H), 7.96 (d, 1H), 7.92 (d, 1H), 7.83 (d, 1H), 7.69 (t, 1H), 7.64-7.50 (m, 3H), 7.32 (dd, 1H), 6.67 (d, 1H), 5.12 (s, 2H), 4.88 (s, 2H), 4.73 (s, 2H), 2.52 (s, 3H). MS m/z (ES+): 533.42 (M+H+).
-
- The coupling of 4′-[(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amino]-biphenyl-2-sulfonic acid tert-butylamide (2) (190 mg, 0.42 mmol) and α-bromo-p-tolunitrile (90 mg, 0.46 mmol), following the procedure described in Example 13, gave 4′-{[5-(3-cyano-benzyloxy)-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl]-amino}-biphenyl-2-sulfonic acid tert-butylamide (58) (149 mg, 62% yield) as a colorless solid.
- 1H-NMR (CDCl3): δ 8.39 (s, 1H), 8.16 (d, 1H), 7.83 (s, 1H), 7.75-7.68 (m, 2H), 7.59-7.53 (m, 2H), 7.49-7.41 (m, 3H), 7.31 (d, 2H), 6.87 (d, 2H), 5.03 (s, 2H), 4.81 (s, 2H), 4.46 (s, 2H), 3.70 (s, 1H), 2.58 (s, 3H), 1.02 (s, 9H).
-
- The conversion of nitrile (17) to amidine (18) was carried out as described in Example 14.
- 1H-NMR (CD3OD): δ 8.30 (s, 1H), 8.07 (d, 1H), 8.01 (s, 1H), 7.92 (d, 1H), 7.84 (d, 1H), 7.70 (t, 1H) 7.58 (t, 1H), 7.46 (t, 1H), 7.32 (d, 1H), 7.24 (d, 2H), 6.77 (d, 2H), 5.11 (s, 2H), 4.58 (s, 2H), 3.36 (s, 2H), 2.52 (s, 3H). MS m/z (ES+): 532.37 (M+H+).
-
Compound (19) was prepared according to the procedure described in Example 11 from 3-bromoanaline (2.08 g, 12.1 mmol) and 2-tert-butylsulfamoyl-phenylboronic acid (2.83 g, 11 mmol). The crude mixture was purified by column chromatography over silica gel using a hexane ethyl acetate (1:1) mixture as eluant to give 2.6 g (84%) of (19). - 1H-NMR (CDCl3): δ 8.15 (dd, 1H), 7.54 (dt, 1H), 7.45 (dt, 1H), 7.33 (dd, 1H), 7.23 (t, 1H), 6.88 (s, 1H), 6.85 (d, 1H), 6.74 (dd, 1H), 3.76 (s, 1H), 3.40 (br s, 2H), 1.0 (s, 9H).
-
Compound (20) was prepared according to the procedure described in Example 1 from biphenyl amine (19) (913 mg, 3 mmol) and 2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridine-5-carbaldehyde (622 mg, 3 mmol). The crude mixture was purified by column chromatography over silica gel using a hexane/ethyl acetate (1:1) mixture as eluant to give 167 mg (11%) of (20). - 1H-NMR (CDCl3): δ 8.13 (dd, 1H), 8.02 (s, 1H), 7.55 (dt, 1H), 7.42 (dt, 1H), 7.33 (dd, 1H), 7.26 (t, 1H), 6.90 (s, 1H), 6.82 (dd, 1H), 6.68 (dd, 1H), 4.88 (s, 2H), 4.20 (s, 2H), 3.96 (br s, 1H), 3.66 (s, 1H), 2.40 (s, 3H), 1.54 (s, 6H), 0.97 (s, 9H).
-
Compound (20) (105 mg, 0.21 mmol) was dissolved in anhydrous methanol (30 ml), and the solution was cooled to 5° C. then saturated with HCl gas. The solution was allowed to slowly warm to room temperature and stirred overnight. The remaining HCl was removed with a steady stream of nitrogen, and the trace amounts of remaining acid neutralized with 7 N methanolic ammonia. The solvents were removed and the residue purified by column chromatography over silica gel using a dichloromethane/methanol (9:1) mixture as eluant to furnish (21) (52 mg, 62%) as a white powder. - 1H-NMR (CD3OD): δ 8.08 (dd, 1H), 7.89 (s, 1H), 7.60 (dt, 1H), 7.50 (dt, 1H), 7.34 (dd, 1H), 7.21 (dt, 1H), 6.76-6.70 (m, 3H), 4.96 (s, 2H), 4.33 (s, 2H), 2.41 (s, 3H). MS m/z (ES+): 400.26 (M+H+).
-
- Compound (22) was prepared according to the procedure described in Example 13 from (5) (156 mg, 0.32 mmol) and α-bromo-m-tolunitrile (69 mg, 0.35 mmol). The crude mixture was purified by column chromatography over silica gel using a mixture of dichloromethane/methyl alcohol (gradient from 1:0 to 9:1) as eluant gave 100 mg (52%) of (22).
- 1H-NMR (CD3OD): δ 8.49 (br s, 1H), 8.12 (dd, 1H), 7.94-7.91 (m, 3H), 7.85 (d, 1H), 7.78 (dd, 1H), 7.63-7.61 (m, 2H), 7.6-7.53 (m, 3H), 7.32 (dd, 1H), 5.18 (s, 2H), 4.96 (s, 2H), 4.90 (s, 2H), 2.7 (s, 3H), 1.06 (s, 9H).
-
Compound (23) was prepared according to the procedure described in Example 14 from (22) (100 mg, 0.17 mmol). The crude mixture was purified by reverse phase preparatory HPLC (Waters XTerra® Prep RP18 OBD™ (10 μM), 19×250 mm)) using 10% to 100% acetonitrile versus 0.1% aqueous trifluoroacetic acid to provide 30 mg, (32%) of (23). - 1H-NMR (CD3OD): δ 8.44 (s, 1H), 8.12 (dd, 1H), 7.99 (br s, 1H), 7.93-7.89 (m, 3H), 7.84 (dd, 1H), 7.70 (t, 1H), 7.63 (dd, 1H), 7.58 (dd, 1H), 7.55-7.52 (m, 2H), 7.34 (dd, 1H), 5.20 (s, 2H), 4.95 (s, 2H), 4.83 (s, 2H), 2.52 (s, 3H). MS m/z (ES+): 560.57 (M+H+).
-
Compound (24) was prepared according to the procedure described in Example 13 from (7) (85 mg, 0.19 mmol) and α-bromo-m-tolunitrile (40 mg, 0.2 mmol). The crude mixture was purified by column chromatography over silica gel using a dichloromethane/methyl alcohol (9:1) mixture as eluant to give 62 mg (58%) of (24). - 1H-NMR (CDCl3): δ 8.33 (br s, 1H), 8.13 (dd, 1H), 7.72 (br s, 1H), 7.64 (m, 2H), 7.52 (m, 2H), 7.45 (dd, 1H), 7.38-7.35 (m, 2H), 7.32 (dd, 1H), 6.76 (m, 2H), 4.96 (s, 2H), 4.79 (s, 2H), 4.42 (s, 2H), 3.7 (s, 1H), 2.60 (s, 3H), 1.02 (s, 9H).
-
Compound (25) was prepared according to the procedure described in Example 14 from (24) (62 mg, 0.11 mmol). The crude mixture was purified by column chromatography over silica gel using a dichloromethane/methanol (gradient from 19:1 to 4:1) mixture as eluant to give 5 mg, (9%) of (25). The major product (33 mg, 56%) was the corresponding benzimidic acid methyl ester (MS m/z (ES+): 547.42 (M+H+)) as determined by MS. - 1H-NMR (CD3OD): δ 8.12 (s, 1H), 7.88 (dd, 1H), 7.75 (br s, 1H), 7.58 (dd, 1H), 7.55 (dd, 1H), 7.44-7.37 (m, 2H), 7.29 (dt, 1H), 7.12 (dd, 1H), 7.04 (d, 2H), 6.55 (d, 2H), 4.92 (s, 2H), 4.58 (s, 2H), 4.21 (s, 2H), 2.4 (s, 3H). MS m/z (ES+): 532.43 (M+H+).
-
Compound (26) was prepared according to the procedure described in Example 17 from (19) (1 g, 3.3 mmol) and pyridoxal hydrochloride (802 mg, 3.9 mmol). The crude product was purified by column chromatography over silica gel using a dichloromethane/methanol (9:1) mixture as eluant to give 389 mg (26%) of (26). - 1H-NMR (CDCl3): δ 8.15 (dd, 1H), 7.88 (s, 1H), 7.53 (t, 1H), 7.49 (t, 1H), 7.35-7.27 (m, 2H), 7.1 (s, 1H), 6.98 (d, 1H), 6.88 (d, 1H), 4.65 (s, 2H), 4.61 (s, 2H), 2.42 (s, 3H), 1.01 (s, 9H).
-
Compound (27) was prepared according to the procedure described in Example 13 from (7) (184 mg, 0.4 mmol) and α-bromo-p-tolunitrile (87 mg, 0.44 mmol). The crude mixture was purified by column chromatography over silica gel using a dichloromethane/methyl alcohol (9:1) mixture to furnish 118 mg (51%) of (27). - 1H-NMR (CDCl3): δ 8.27 (s, 1H), 8.14 (dd, 1H), 7.63 (d, 2H), 7.59-7.47 (m, 2H), 7.53 (d, 2H), 7.3 (dd, 1H), 7.23 (d, 1H), 7.0 (m, 1H), 6.79 (d, 1H), 6.7 (dd, 1H), 4.96 (s, 2H), 4.73 (s, 2H), 4.43 (s, 2H), 3.74 (s, 1H), 2.54 (s, 3H), 0.95 (s, 9H).
-
- 1H-NMR (CD3OD): δ 8.28 (s, 1H), 8.08 (dd, 1H), 7.77 (d, 2H), 7.66 (d, 2H), 7.56 (dt, 1H), 7.5 (dt, 1H), 7.29 (dd, 1H), 7.15 (t, 1H), 6.79 (t, 1H), 6.72-6.69 (m, 2H), 5.08 (s, 2H), 4.76 (s, 2H), 4.37 (s, 2H), 2.53 (s, 3H). MS m/z (ES+): 532.37 (M+H+).
-
Compound (29) was prepared according to the procedure described in Example 13 from (9) (137 mg, 0.29 mmol) and α-bromo-p-tolunitrile (62 mg, 0.45 mmol). The crude mixture was purified by column chromatography over silica gel using a dichloromethane/methyl alcohol (19:1) mixture as eluant to give 94 mg (55%) of (29). - 1H-NMR (CD3OD): δ 8.28 (s, 1H), 8.07 (dd, 1H), 7.97 (br s, 1H), 7.71 (d, 2H), 7.63 (d, 2H), 7.58 (dt, 1H), 7.47 (dt, 1H), 7.32 (dd, 1H), 7.12 (dd, 1H), 7.04 (dd, 1H), 6.87 (t, 1H), 5.07 (s, 2H), 4.77 (s, 2H), 4,47 (s, 2H), 2.54 (s, 3H), 0.98 (s, 9H).
- 19F-NMR (CD3OD; 1H-decoupled): δ −137.9.
-
- 1H-NMR (MeOH-d4): δ 8.29 (s, 1H), 8.07 (dd, 1H), 7.81 (d, 2H), 7.69 (d, 1H), 7.58 (dt, 1H), 7.49 (dt, 1H), 7.3 (dd, 1H), 7.08 (dd, 1H), 7.04 (dd, 1H), 6.85 (t, 1H), 5.12 (s, 2H), 4.78 (s, 2H), 4.47 (s, 2H), 2.57 (s, 3H).
- 19F-NMR (CD3OD; 1H-decoupled): 6-137.8. MS m/z (ES+): 550.56 (M+H+).
-
- 1H-NMR (CD3OD): δ 7.94 (d, 1H), 7.89 (s, 1H), 7.81 (s, 1H), 7.45 (m, 4H), 7.22 (dd, 1H), 6.51 (d, 1H), 4.87 (s, 2H), 4.44 (s, 2H), 2.31 (s, 3H).
-
- 1H-NMR (CD3OD): δ 8.08 (dd, 1H), 7.86 (s, 1H), 7.59 (dt, 1H), 7.5 (dt, 1H), 7.32 (dd), 7.24 (dt, 1H), 6.88-6.83 (m, 3H), 4.70 (s, 2H), 4.53 (s, 2H), 2.4 (s, 2H).
- Platelet rich plasma (PRP) was obtained by drawing whole blood from normal human donors (not on any medication) into sodium citrate tubes (3.2%), and centrifuging at 160×g for about 10 minutes. Platelet poor plasma (PPP) was obtained by centrifuging the remainder of the sample after the platelets were removed at 800×g for about 10 minutes. The PRP was adjusted to a count of 280×109/L using a mixture of PRP and PPP. The platelets (200 μL) were incubated with the test compounds (25 μL) adjusted to various concentrations (from a 250 μM stock solution) for about 30 minutes at room temperature (approximate final platelet count in the incubation mixture of 250×109/L). The samples were incubated for about 3 minutes at about 37° C., and then transferred to the mixing wells of a Chrono-log 4 channel aggregometer (Chrono-log Corp., Havertown, Pa.). After baselines were established, the agonist (25 μL of 40 μM ADP (Sigma, St. Louis, Mo.) or 25 μL of 50 μg/mL and 10 μg/mL collagen (Helena Laboratories, Beaumont, Tex.) or 25 μL of 120 μM thrombin receptor activating peptide (TRAP) (Sigma)) was then added. Aggregation was monitored for 5 minutes at 37° C. with stirring (1000 rpm). The amplitude and slope of each tracing were calculated to determine the amount of aggregation. Control samples were performed using only solvent. The % reduction in aggregation was calculated for each sample compared to the proper solvent control. See Table 1.
TABLE 1 Platelet inhibition % Reduction in Aggregation Concentration Collagen Collagen ADP TRAP Compound (μM) (5 μg/mL) (1 μg/mL) (4 μM) (12 μM) 3 250 5 0 0 6 6 250 0 5 0 1 14 250 5 15 10 9 16 250 0 14 3 1.3 18 250 9 23 50 74 21 250 0 4 14 0 28 250 15 10 26 11 30 100 19 57 23 57 33 500 15 5 4 1 34 250 1 41 63 93
Compound 33 is Compound XXXV in U.S. Pat. No. 6,417,204 B1, which is hereby incorporated by reference, and compound 34 is Compound XL in U.S. Pat. No. 6,417,204 B1 - Compounds were evaluated for inhibition of serine protease activity.
- Methods
- The enzymes factor Xa (fXa), thrombin (factor IIa or fIIa), and trypsin were purchased from Haematologic Technologies Inc. (Essex Junction, Vt.). The substrates Pefachromes Xa, Th, and Try were purchased from Centerchem Inc. (Stamford, Conn.). Varying concentrations of the sulfonamide compounds were incubated for 30 min at room temperature with purified activated human enzyme in the appropriate buffer. Various concentrations of the corresponding synthetic substrate were added, and activity was measured at 37° C. by monitoring absorbance at 405 nm for 15 min with a Flurostar Optima plate reader. Each assay had a final volume of 200 μL, and assays were performed in 96-well plates. For IC50 determinations, 300 μM of substrate was tested against five concentrations (50, 100, 200, 300, and 500 μM) of test compound plus control (run in duplicate). For controls, the appropriate percentage of solvent was used instead of test compound. The specific activity (ΔA405/min/nM protein), and the percent activity was calculated for each data point. The IC50 was calculated by linear regression of log[test compound] vs. % activity. The enzyme activity of the sulfonamide compound was determined using the Enzyme Kinetics Module of Sigmaplot 8.0 (SPSS Inc.)
- The final concentration of human Factor Xa was 2 nM in a Tris/NaCl buffer (pH 7.5) containing 0.25% (w/v) polyethylene glycol (MW 8000). The substrate employed was Pefachrome Xa.
- The final concentration of human thrombin was 2 nM in a Tris/NaCl buffer (pH 8.3) containing 0.125% (w/v) bovine serum albumin. The substrate used was Pefachrome Th.
- The final concentration of human trypsin was 2 nM in a Tris/NaCl buffer (pH 7.5) containing 0.25% (w/v) bovine serum albumin and 20 μM CaCl2. The substrate used was Pefachrome Try.
- The serine protease activity (fXa, fIIa and trypsin) of the pyridoxine sulfonamides (Table 2) showed that some of these compounds may serve as compounds with improved anticoagulant (possibly anti-fxa) properties. Compounds 3, 8, 31, and 32 were virtually inactive against all three serine proteases (>1000 μM). Unexpectedly, the N-blocked sulfonamides 2, 7, and 12 displayed some enhanced, albeit low, inhibition of fXa activity over their deprotected counterparts 3, 8, and 31, respectively. An exception to this was noted in the case where the linker contained an amide as exemplified by compounds 5 and 6, where both the N-protected and free sulfonamide showed similar fXa activity. As could be expected, significant improvement in inhibition of flia and especially fXa activity was observed upon incorporation of the basic benzamidine moiety that is anticipated to interact with Asp 189 in the S1 pocket. For the pyridoxine scaffold described herein, the 4-position biaryl isomer (compound 25) displayed similar overall inhibitory properties when compared to the corresponding 5-position biaryl isomers (e.g., compound 14), with a slight improvement in inhibition of fXa activity observed with the former. However, neither of these arrangements showed significant improvements in terms of selectivity over trypsin. Also, insertion of a carbonyl improved inhibition of fIIa activity (see 23 versus 14).
TABLE 2 Inhibition of serine protease (fXa, fIIa and Trypsin) activity by sulfonamides Compound IC50 (fXa) (μM) IC50 (fIIa) (μM) IC50 (Trypsin) (μM) 2 329 >1000 >1000 3 >1000 >1000 >1000 5 362 >1000 >1000 6 306 >1000 >1000 7 197 >1000 >1000 8 >1000 >1000 >1000 12 317 >1000 >1000 14 15 862 12 16 11 >1000 11 18 32 370 43 21 326 >1000 >1000 23 5 97 24 25 4 >1000 15 28 17 476 3 30 18 171 4 31 >1000 >1000 >1000 32 >1000 >1000 >1000 33 105 300 18 34 29 >1000 4
Claims (33)
1. A method of inhibiting serine protease activity comprising:
administering a compound of the formula:
wherein
R1 is —OH, —O-alkyl, —(CH2)n′OH where n′ is an integer from 1 to 8, alkyl, cycloalkyl, or O-alkyl-aryl-R4, where R4 is —CN or amidine;
R2 is alkyl; —(CH2)n′OH where n′ is as defined above; —(CH2)nCOOH where n is an integer from 0 to 8; —(CH2)nCOO(CH2)nCH3 where n is as defined above; or R5 where R5 is (CH2)n-aryl-R6 where n is as defined above and R6 is SO2NH2 or SO2NHC(CH3)3; (CH2)n-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-aryl-R6, where n and R6 are as defined above; or —(CH2)n—NH-aryl-R6, where n and R6 are as defined above;
R3 is alkyl; —(CH2)n′OH where n′ is as defined above; or R5 where R5 is (CH2)n—NH-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-R where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6 where n and R6 are as defined above; or (CH2)n—NH—CO-aryl-aryl-R6 where n and R6 are as defined above;
further wherein
R2 is alkyl or —(CH2)n′OH where n′ is as defined above, and R3 is R5; or
R2 is R5 and R3 is alkyl or —(CH2)n′OH where n′ is as defined above; and
R1 and R2 when taken together form compounds of formula II,
wherein R7 and R8 are independently H or CH3, and R5 is as defined above;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein said serine protease is Factor Xa.
3. The method of claim 1 , wherein said serine protease is Factor IIa.
4. The method of claim 1 , wherein said serine protease is trypsin.
5. The method of claim 1 , wherein at least one alkyl is substituted with one or more of fluorine, chlorine, alkoxy groups having 1 to 8 carbon atoms, or amido groups having from 1 to 8 carbon atoms.
6. The method of claim 5 , wherein the alkoxy group is methoxy or ethoxy.
7. The method of claim 5 , wherein the amido group is acetamido.
8. The method of claim 1 , wherein the aryl group is a phenyl group or a naphthyl group.
9. The method of claim 1 , wherein the aryl group is substituted with one or more of fluorine, chlorine, bromine, alkyl groups having 1 to 8 carbon atoms, alkoxy groups having 1 to 8 carbon atoms, alkoxyalkyl groups having 1 to 8 carbon atoms, or amido groups having 1 to 8 carbon atoms.
10. The method of claim 9 , wherein the alkyl group is methyl or ethyl.
11. The method of claim 9 , wherein the alkoxy group is methoxy or ethoxy.
12. The method of claim 9 , wherein the amido group is acetamido.
13. The method of claim 1 , wherein the aryl group is substituted with one or more functional groups.
14. The method of claim 13 , wherein the functional group is a hydroxy group, carboxy group, or acetoxy group.
15. A method of inhibiting serine protease activity comprising:
administering a compound of the formula
wherein
R1 is OH; OCH3; OCH2-(4-tert-Butyl-phenyl); or
where R4 is —CN or amidine;
R2 is (CH2)mOH, where m=0 to 8; or R5, where R5 is
where W is (CH2)n where n=1, 2, or 3; where X is C=0 or (CH2)n′, where n′=0, 1, 2, or 3; Y is CH, CF, or N; and R6 is
R3 is (CH2)mOH, where m is as defined above; or R5, where R5 is as defined above;
further wherein
R2 is (CH2)mOH, where m is as defined above, and R3 is R5; or
R2 is R5 and R3 is (CH2)mOH, where m is as defined above; and
R1 and R2 when taken together form a compound of formula IV
wherein R7 and R8 are independently H or CH3; and R5 is as defined above; or a pharmaceutically acceptable salt thereof.
16. The method of claim 15 , wherein said serine protease is Factor Xa.
17. The method of claim 15 , wherein said serine protease is Factor Ia.
18. The method of claim 15 , wherein said serine protease is trypsin.
19. The method of claim 15 , wherein said compound is administered enterally, parenterally, or by inhalation.
20. The method of claim 15 , wherein the compound is administered concurrently with another therapeutic agent.
21. The method of claim 20 , wherein said other therapeutic agent is an anti-platelet agent, glycoprotein IIb/IIIa inhibitor, or anticoagulant.
22. The method of claim 21 , wherein said anti-platelet agent is clopidogrel, aspirin, or dipyridamole.
23. The method of claim 21 , wherein said glycoprotein IIb/IIIa inhibitor is eptifibatide.
24. The method of claim 21 , wherein said anticoagulant is unfractionated heparin, low molecular weight heparin, hirudin, or argatroban.
25. A method of inhibiting in vitro serine protease activity comprising:
contacting an isolated cell with a compound of the formula:
wherein
R1 is —OH, —O-alkyl, —(CH2)n′OH where n′ is an integer from 1 to 8, alkyl, cycloalkyl, or O-alkyl-aryl-R4, where R4 is —CN or amidine;
R2 is alkyl; —(CH2)n′OH where n′ is as defined above; —(CH2)nCOOH where n is an integer from 0 to 8; —(CH2)nCOO(CH2)nCH3 where n is as defined above; or R5 where R5 is (CH2)n-aryl-R6 where n is as defined above and R6 is SO2NH2 or SO2NHC(CH3)3; (CH2)n-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-aryl-R6, where n and R6 are as defined above; or —(CH2)n—NH-aryl-R6, where n and R6 are as defined above;
R3 is alkyl; —(CH2)n′OH where n′ is as defined above; or R5 where R5 is (CH2)n—NH-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-R6 where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6 where n and R6 are as defined above; or (CH2)n—NH—CO-aryl-aryl-R6 where n and R6 are as defined above;
further wherein
R2 is alkyl or —(CH2)n′OH where n′ is as defined above, and R3 is R5; or
R2 is R5 and R3 is alkyl or —(CH2)n′OH where n′ is as defined above; and
R1 and R2 when taken together form compounds of formula II,
wherein R7 and R8 are independently H or CH3, and R5 is as defined above; or a pharmaceutically acceptable salt thereof.
26. A method of inhibiting serine protease activity comprising:
contacting an organism with a compound of the formula:
wherein
R1 is —OH, —O-alkyl, —(CH2)n′OH where n′ is an integer from 1 to 8, alkyl, cycloalkyl, or O-alkyl-aryl-R4, where R4 is —CN or amidine;
R2 is alkyl; —(CH2)n′OH where n′ is as defined above; —(CH2)nCOOH where n is an integer from 0 to 8; —(CH2)nCOO(CH2)nCH3 where n is as defined above; or R5 where R5 is (CH2)n-aryl-R6 where n is as defined above and R6 is SO2NH2 or SO2NHC(CH3)3; (CH2)n-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-aryl-R6, where n and R6 are as defined above; or —(CH2)n—NH-aryl-R6, where n and R6 are as defined above;
R3 is alkyl; —(CH2)nOH where n′ is as defined above; or R5 where R5 is (CH2)n—NH-aryl-R6, where n and R6 are as defined above; (CH2)n—NH—CO-aryl-R6 where n and R6 are as defined above; (CH2)n—NH-aryl-aryl-R6 where n and R6 are as defined above; or (CH2)n—NH—CO-aryl-aryl-R6 where n and R6 are as defined above;
further wherein
R2 is alkyl or —(CH2)n′OH where n′ is as defined above, and R3 is R5; or
R2 is R5 and R3 is alkyl or —(CH2)n′OH where n′ is as defined above; and
R1 and R2 when taken together form compounds of formula II,
wherein R7 and R8 are independently H or CH3, and R5 is as defined above; or a pharmaceutically acceptable salt thereof.
27. A compound of the formula
wherein
R1 is OH; OCH3; OCH2-(4-tert-Butyl-phenyl); or
where R4 is —CN or amidine;
R2 is (CH2)mOH, where m=0 to 8; or R5, where R5 is
where W is (CH2)n where n=1, 2, or 3; where X is C=0 or (CH2)n′, where n′=0, 1, 2, or
3; Y is CH, CF, or N; and R6 is
further wherein
R2 is (CH2)mOH, where m is as defined above, and R3 is R5; or
R2 is R5 and R3 is (CH2)mOH, where m is as defined above; and
R1 and R2 when taken together form a compound of formula IV
wherein R7 and R8 are independently H or CH3; and R5 is as defined above; or a pharmaceutically acceptable salt thereof.
28. A method of treating cardiovascular or related diseases in a mammal comprising administering a therapeutically effective amount of a compound of claim 27 .
29. The method of claim 29 , wherein the compound is administered concurrently with another therapeutic agent.
30. The method of claim 29 , wherein said other therapeutic agent is an anti-platelet agent, glycoprotein IIb/IIIa inhibitor, or anticoagulant.
31. The method of claim 30 , wherein said anti-platelet agent is clopidogrel, aspirin, or dipyridamole.
32. The method of claim 30 , wherein said glycoprotein IIb/IIIa inhibitor is eptifibatide.
33. The method of claim 30 , wherein said anticoagulant is unfractionated heparin, low molecular weigh heparins, hirudin, or argatroban.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/672,140 US20070142270A1 (en) | 2004-10-28 | 2007-02-07 | Aryl Sulfonic Pyridoxines as Antiplatelet Agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/974,707 US7459468B2 (en) | 2004-10-28 | 2004-10-28 | Aryl sulfonic pyridoxines as antiplatelet agents |
US11/672,140 US20070142270A1 (en) | 2004-10-28 | 2007-02-07 | Aryl Sulfonic Pyridoxines as Antiplatelet Agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/974,707 Continuation-In-Part US7459468B2 (en) | 2004-10-28 | 2004-10-28 | Aryl sulfonic pyridoxines as antiplatelet agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070142270A1 true US20070142270A1 (en) | 2007-06-21 |
Family
ID=36226998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/974,707 Expired - Fee Related US7459468B2 (en) | 2004-10-28 | 2004-10-28 | Aryl sulfonic pyridoxines as antiplatelet agents |
US11/672,140 Abandoned US20070142270A1 (en) | 2004-10-28 | 2007-02-07 | Aryl Sulfonic Pyridoxines as Antiplatelet Agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/974,707 Expired - Fee Related US7459468B2 (en) | 2004-10-28 | 2004-10-28 | Aryl sulfonic pyridoxines as antiplatelet agents |
Country Status (6)
Country | Link |
---|---|
US (2) | US7459468B2 (en) |
EP (1) | EP1824826A4 (en) |
JP (1) | JP2008517955A (en) |
AU (1) | AU2005299220A1 (en) |
CA (1) | CA2585177A1 (en) |
WO (1) | WO2006045204A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008847A1 (en) * | 1999-07-13 | 2003-01-09 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US20040171588A1 (en) * | 2000-02-29 | 2004-09-02 | Wasimul Haque | Cardioprotective phosphonates and malonates |
US20050107443A1 (en) * | 2000-07-07 | 2005-05-19 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
US20060094748A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
US20060094761A1 (en) * | 2004-10-28 | 2006-05-04 | Wasimul Haque | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20060148763A1 (en) * | 2005-01-05 | 2006-07-06 | Friesen Albert D | Compounds and methods for regulating triglyceride levels |
US20060241083A1 (en) * | 2003-03-17 | 2006-10-26 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
US20070032456A1 (en) * | 2003-03-27 | 2007-02-08 | Friesen Albert D | Modulation of cell death |
US20070149485A1 (en) * | 2005-11-28 | 2007-06-28 | Medicure International, Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
US20070243249A1 (en) * | 2004-11-26 | 2007-10-18 | Friesen Albert D | Novel formulation of pyridoxal-5'-phosphate and method of preparation |
US20080213364A1 (en) * | 2004-11-26 | 2008-09-04 | Medicure International, Inc. | Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation |
US20090018106A1 (en) * | 2005-03-30 | 2009-01-15 | Medicure International Inc. | Intravenous formulations of pyridoxal 5'- phosphate and method of preparation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8137397B2 (en) * | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
Citations (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3206463A (en) * | 1965-09-14 | Pyridoxine aspartate and its process of preparation | ||
US3227724A (en) * | 1962-01-16 | 1966-01-04 | Merck & Co Inc | Process for preparing 2-methyl-3-hydroxypyridines |
US3227721A (en) * | 1965-05-24 | 1966-01-04 | Merck & Co Inc | Process for preparing 2-methyl-3-hydroxypyridines |
US3632806A (en) * | 1967-10-16 | 1972-01-04 | Tanabe Seiyaku Co | Novel n - pyridylmethylidene - homo-cysteine thiolactone compound and the preparation thereof |
US3910921A (en) * | 1970-01-08 | 1975-10-07 | Soc D Etudes Prod Chimique | Papaverine monopyridoxal phosphate |
US3987177A (en) * | 1974-06-27 | 1976-10-19 | Synthelabo | Vincaminic acid esters |
US4012377A (en) * | 1967-03-31 | 1977-03-15 | Glaxo Laboratories Limited | Oxadiazole and oxadiazoline derivatives |
US4032534A (en) * | 1973-03-22 | 1977-06-28 | Ferlus-Chimie S.A. | Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids |
US4036844A (en) * | 1972-04-04 | 1977-07-19 | Beecham Group Limited | Aryloxypyridines |
US4053607A (en) * | 1972-04-04 | 1977-10-11 | Beecham Group Limited | Aryloxypyridine for treating hyperglycaemia |
US4137316A (en) * | 1976-05-11 | 1979-01-30 | Societe D'etudes De Produits Chimiques | Anti-depressive vincamine pyridoxal-5-phosphate |
US4167562A (en) * | 1978-08-28 | 1979-09-11 | Evers H Ray | Method and composition for treating arteriosclerosis |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4374841A (en) * | 1980-05-19 | 1983-02-22 | S. A. Labaz N.V. | Pyridoxine derivatives, and use in therapeutics |
US4515771A (en) * | 1983-04-11 | 1985-05-07 | Fine Daniel H | Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition |
US4567179A (en) * | 1984-10-11 | 1986-01-28 | Pfizer, Inc. | Antiinflammatory salts of piroxicam |
US4569939A (en) * | 1983-11-16 | 1986-02-11 | Societe De Conseils De Recherches Et D'applications Scientifiques | Diuretic 6-vinyl-furo-(3,4-c)-pyridine derivatives |
US4569938A (en) * | 1983-11-17 | 1986-02-11 | Societe De Conseils De Recherches Et D'applications Scientifiques | Diuretic, antihypertensive and antihistaminic 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives |
US4581363A (en) * | 1983-04-05 | 1986-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Furo-(3,4-C)-pyridine derivatives and therapeutic compositions containing the same |
US4605741A (en) * | 1985-11-13 | 1986-08-12 | Lisapharma Spa | Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate |
US4696920A (en) * | 1984-07-18 | 1987-09-29 | Symphar S.A. | Certain 2-substituted 1,3-propylidenediphosphonate derivatives, pharmaceutical compositions containing them and their use as antihypertensive agents |
US4730042A (en) * | 1985-06-01 | 1988-03-08 | Basf Aktiengesellschaft | Compounds 1 or 3-hydroxy-4-benzyl-6-methyl-7-(4-isopropylamino-butoxy)-1,3-dihydro[3,4-C]pyridine and 2-methyl-3-(4-isopropyl-aminobutoxy)-4-(1'-morphilinomethyl)-5-hydroxymethyl-6-benzyl pyridine, useful for treating cardiac arrhythmias |
US4735950A (en) * | 1983-04-05 | 1988-04-05 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) | Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same |
US4735956A (en) * | 1985-09-13 | 1988-04-05 | Merck & Co., Inc. | Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers |
US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
US4898879A (en) * | 1981-06-29 | 1990-02-06 | Baxter International Inc. | Nurtitional composition for management of hepatic failure |
US4962121A (en) * | 1987-04-22 | 1990-10-09 | Anders Hamberger | Method and composition for treating neurological diseases such as migraine |
US5001115A (en) * | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
US5118505A (en) * | 1988-01-28 | 1992-06-02 | Koeltringer Peter | Combination preparation for the treatment of nerve cell and nerve fibre diseases and injury |
US5130311A (en) * | 1990-11-20 | 1992-07-14 | Adir Et Compagnie | Oxazolopyridine compounds, compositions and use |
US5130324A (en) * | 1984-03-19 | 1992-07-14 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US5132115A (en) * | 1986-04-17 | 1992-07-21 | Karin Wolter | Planar therapeutic system, process for its production and utilization |
US5155116A (en) * | 1990-06-29 | 1992-10-13 | Adir Et Compagnie | Medicinal oxazolopyridine compounds |
US5210083A (en) * | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
US5213813A (en) * | 1987-05-29 | 1993-05-25 | The University Of Vermont | Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer |
US5254572A (en) * | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
US5254557A (en) * | 1988-05-09 | 1993-10-19 | Beecham Group P.L.C. | Compound and treatment |
US5278154A (en) * | 1991-07-03 | 1994-01-11 | Adir Et Compagnie | New vanadium complexes |
US5288716A (en) * | 1987-02-18 | 1994-02-22 | Ulrich Speck | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
US5326757A (en) * | 1992-01-06 | 1994-07-05 | Health Maintenance Programs, Inc. | Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
US5328453A (en) * | 1988-12-21 | 1994-07-12 | Drug Delivery Systems Inc. | Method for enhancing transdermal drug delivery of electrical drug applicators |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
US5420112A (en) * | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US5441972A (en) * | 1993-04-02 | 1995-08-15 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical use of pyridoxal derivative |
US5504090A (en) * | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5594004A (en) * | 1993-03-17 | 1997-01-14 | Meiji Seika Kabushiki Kaisha | Compound with platelet aggregation inhibitor activity |
US5631271A (en) * | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
US5633228A (en) * | 1992-06-12 | 1997-05-27 | Cephalon, Inc., | Prevention and treatment of peripheral neuropathy |
US5728684A (en) * | 1991-05-15 | 1998-03-17 | Yale University | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5770215A (en) * | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
US5795873A (en) * | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5858017A (en) * | 1994-12-12 | 1999-01-12 | Omeros Medical Systems, Inc. | Urologic irrigation solution and method for inhibition of pain, inflammation and spasm |
US5874443A (en) * | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5874420A (en) * | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
US5944020A (en) * | 1997-02-25 | 1999-08-31 | Cypros Pharmaceutical Corp. | Use of fructose-1 6-diphosphate as an inotrope drug after cardiopulmonary bypass surgery |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
US6051585A (en) * | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
US6274170B1 (en) * | 1999-02-18 | 2001-08-14 | Richard Heibel | Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same |
US6339085B1 (en) * | 1999-03-08 | 2002-01-15 | The University Of Manitoba | Therapeutics for cardiovascular and related diseases |
US6358960B1 (en) * | 1998-02-17 | 2002-03-19 | Ono Pharmaceutical Co., Ltd. | Amidino derivatives and drugs containing the same as the active ingredient |
US6417204B1 (en) * | 2000-07-07 | 2002-07-09 | Medicure International Inc. | Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics |
US6544547B2 (en) * | 1997-07-14 | 2003-04-08 | N. V. Nutricia | Nutritional composition containing methionine |
US6548519B1 (en) * | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
US20030114424A1 (en) * | 2000-03-28 | 2003-06-19 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6605612B2 (en) * | 2000-02-29 | 2003-08-12 | Medicure International Inc. | Cardioprotective phosohonates and malonates |
US6677356B1 (en) * | 1999-08-24 | 2004-01-13 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
US20040171588A1 (en) * | 2000-02-29 | 2004-09-02 | Wasimul Haque | Cardioprotective phosphonates and malonates |
US6789997B2 (en) * | 1998-06-08 | 2004-09-14 | Stevedoring Services Of America, Inc. | Method and apparatus for pallet removal cargo queuing and stowage of stacks of cartons of frozen animal products |
US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
US20050107443A1 (en) * | 2000-07-07 | 2005-05-19 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
US20060035864A1 (en) * | 2004-08-10 | 2006-02-16 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20060094748A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
US20060094761A1 (en) * | 2004-10-28 | 2006-05-04 | Wasimul Haque | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20060148763A1 (en) * | 2005-01-05 | 2006-07-06 | Friesen Albert D | Compounds and methods for regulating triglyceride levels |
US20070032456A1 (en) * | 2003-03-27 | 2007-02-08 | Friesen Albert D | Modulation of cell death |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20070149485A1 (en) * | 2005-11-28 | 2007-06-28 | Medicure International, Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
US20070167411A1 (en) * | 2003-03-27 | 2007-07-19 | Medicure International Inc. | Compositions for treating angina |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282778A (en) | 1960-09-02 | 1966-11-01 | Lohel Mervyn Joseph | Medicinal preparation containing acetyl salicylic acid and a pyridoxine compound |
US4237118A (en) | 1972-03-06 | 1980-12-02 | Howard Alan N | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
IT1141070B (en) | 1980-09-22 | 1986-10-01 | Luso Farmaco Inst | USE OF ALPHA-KETOGLUTARATE OF PYRIDOXY IN THE PROPHYLAXIS OF HYPERLACTACIDEMIA |
US5272165A (en) | 1984-03-19 | 1993-12-21 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US4837239A (en) | 1985-08-23 | 1989-06-06 | Syntex (U.S.A.) Inc. | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins |
NO179479C (en) | 1988-03-11 | 1996-10-16 | Teikoku Seiyaku Kk | Process for the preparation of an intravaginal pharmaceutical preparation |
DE4016963A1 (en) | 1990-05-25 | 1991-11-28 | Steigerwald Arzneimittelwerk | USE OF MAGNESIUM PYRIDOXAL 5'-PHOSPHATE GLUTAMINATE TO PREVENT ILLNESSES ARISING AS A RESULT OF DISSOLUTION |
US5330743A (en) | 1992-11-12 | 1994-07-19 | Magnetic Research, Inc. | Aminosaccharide contrast agents for magnetic resonance images |
US5569459A (en) | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5833998A (en) | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
US5847008A (en) | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5834446A (en) | 1996-06-21 | 1998-11-10 | Queen's University At Kingston | Nerve process growth modulators |
US6232188B1 (en) * | 1997-07-31 | 2001-05-15 | Texas Instruments Incorporated | CMP-free disposable gate process |
US6323188B1 (en) | 1998-07-01 | 2001-11-27 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins |
US6232170B1 (en) * | 1999-06-16 | 2001-05-15 | International Business Machines Corporation | Method of fabricating trench for SOI merged logic DRAM |
CA2376029A1 (en) | 1999-07-13 | 2001-01-18 | Medicure Inc. | Use of pyridoxin derivatives for the treatment of diabetes and related complications |
GB9920762D0 (en) * | 1999-09-02 | 1999-11-03 | Transense Technologies Plc | Apparatus and method for interrogating a passive sensor |
US20070243249A1 (en) * | 2004-11-26 | 2007-10-18 | Friesen Albert D | Novel formulation of pyridoxal-5'-phosphate and method of preparation |
-
2004
- 2004-10-28 US US10/974,707 patent/US7459468B2/en not_active Expired - Fee Related
-
2005
- 2005-10-28 WO PCT/CA2005/001659 patent/WO2006045204A1/en active Application Filing
- 2005-10-28 JP JP2007538229A patent/JP2008517955A/en active Pending
- 2005-10-28 AU AU2005299220A patent/AU2005299220A1/en not_active Abandoned
- 2005-10-28 CA CA002585177A patent/CA2585177A1/en not_active Abandoned
- 2005-10-28 EP EP05810365A patent/EP1824826A4/en not_active Withdrawn
-
2007
- 2007-02-07 US US11/672,140 patent/US20070142270A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3206463A (en) * | 1965-09-14 | Pyridoxine aspartate and its process of preparation | ||
US3227724A (en) * | 1962-01-16 | 1966-01-04 | Merck & Co Inc | Process for preparing 2-methyl-3-hydroxypyridines |
US3227721A (en) * | 1965-05-24 | 1966-01-04 | Merck & Co Inc | Process for preparing 2-methyl-3-hydroxypyridines |
US4012377A (en) * | 1967-03-31 | 1977-03-15 | Glaxo Laboratories Limited | Oxadiazole and oxadiazoline derivatives |
US3632806A (en) * | 1967-10-16 | 1972-01-04 | Tanabe Seiyaku Co | Novel n - pyridylmethylidene - homo-cysteine thiolactone compound and the preparation thereof |
US3910921A (en) * | 1970-01-08 | 1975-10-07 | Soc D Etudes Prod Chimique | Papaverine monopyridoxal phosphate |
US4036844A (en) * | 1972-04-04 | 1977-07-19 | Beecham Group Limited | Aryloxypyridines |
US4053607A (en) * | 1972-04-04 | 1977-10-11 | Beecham Group Limited | Aryloxypyridine for treating hyperglycaemia |
US4032534A (en) * | 1973-03-22 | 1977-06-28 | Ferlus-Chimie S.A. | Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids |
US3987177A (en) * | 1974-06-27 | 1976-10-19 | Synthelabo | Vincaminic acid esters |
US4137316A (en) * | 1976-05-11 | 1979-01-30 | Societe D'etudes De Produits Chimiques | Anti-depressive vincamine pyridoxal-5-phosphate |
US4167562A (en) * | 1978-08-28 | 1979-09-11 | Evers H Ray | Method and composition for treating arteriosclerosis |
US4374841A (en) * | 1980-05-19 | 1983-02-22 | S. A. Labaz N.V. | Pyridoxine derivatives, and use in therapeutics |
US4898879A (en) * | 1981-06-29 | 1990-02-06 | Baxter International Inc. | Nurtitional composition for management of hepatic failure |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4735950A (en) * | 1983-04-05 | 1988-04-05 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) | Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same |
US4581363A (en) * | 1983-04-05 | 1986-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Furo-(3,4-C)-pyridine derivatives and therapeutic compositions containing the same |
US4515771A (en) * | 1983-04-11 | 1985-05-07 | Fine Daniel H | Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition |
US4569939A (en) * | 1983-11-16 | 1986-02-11 | Societe De Conseils De Recherches Et D'applications Scientifiques | Diuretic 6-vinyl-furo-(3,4-c)-pyridine derivatives |
US4569938A (en) * | 1983-11-17 | 1986-02-11 | Societe De Conseils De Recherches Et D'applications Scientifiques | Diuretic, antihypertensive and antihistaminic 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives |
US5130324A (en) * | 1984-03-19 | 1992-07-14 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US4696920A (en) * | 1984-07-18 | 1987-09-29 | Symphar S.A. | Certain 2-substituted 1,3-propylidenediphosphonate derivatives, pharmaceutical compositions containing them and their use as antihypertensive agents |
US4567179A (en) * | 1984-10-11 | 1986-01-28 | Pfizer, Inc. | Antiinflammatory salts of piroxicam |
US4730042A (en) * | 1985-06-01 | 1988-03-08 | Basf Aktiengesellschaft | Compounds 1 or 3-hydroxy-4-benzyl-6-methyl-7-(4-isopropylamino-butoxy)-1,3-dihydro[3,4-C]pyridine and 2-methyl-3-(4-isopropyl-aminobutoxy)-4-(1'-morphilinomethyl)-5-hydroxymethyl-6-benzyl pyridine, useful for treating cardiac arrhythmias |
US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
US4735956A (en) * | 1985-09-13 | 1988-04-05 | Merck & Co., Inc. | Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers |
US4605741A (en) * | 1985-11-13 | 1986-08-12 | Lisapharma Spa | Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate |
US5132115A (en) * | 1986-04-17 | 1992-07-21 | Karin Wolter | Planar therapeutic system, process for its production and utilization |
US5210083A (en) * | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5631271A (en) * | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
US5288716A (en) * | 1987-02-18 | 1994-02-22 | Ulrich Speck | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
US6066659A (en) * | 1987-02-18 | 2000-05-23 | Steigerwald Arzneimittelwerk Gmbh | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
US4962121A (en) * | 1987-04-22 | 1990-10-09 | Anders Hamberger | Method and composition for treating neurological diseases such as migraine |
US5213813A (en) * | 1987-05-29 | 1993-05-25 | The University Of Vermont | Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer |
US5254572A (en) * | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
US5118505A (en) * | 1988-01-28 | 1992-06-02 | Koeltringer Peter | Combination preparation for the treatment of nerve cell and nerve fibre diseases and injury |
US5254557A (en) * | 1988-05-09 | 1993-10-19 | Beecham Group P.L.C. | Compound and treatment |
US5328453A (en) * | 1988-12-21 | 1994-07-12 | Drug Delivery Systems Inc. | Method for enhancing transdermal drug delivery of electrical drug applicators |
US5001115A (en) * | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
US5155116A (en) * | 1990-06-29 | 1992-10-13 | Adir Et Compagnie | Medicinal oxazolopyridine compounds |
US5130311A (en) * | 1990-11-20 | 1992-07-14 | Adir Et Compagnie | Oxazolopyridine compounds, compositions and use |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
US5728684A (en) * | 1991-05-15 | 1998-03-17 | Yale University | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
US5278154A (en) * | 1991-07-03 | 1994-01-11 | Adir Et Compagnie | New vanadium complexes |
US5326757A (en) * | 1992-01-06 | 1994-07-05 | Health Maintenance Programs, Inc. | Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
US5633228A (en) * | 1992-06-12 | 1997-05-27 | Cephalon, Inc., | Prevention and treatment of peripheral neuropathy |
US5648335A (en) * | 1992-06-12 | 1997-07-15 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
US5420112A (en) * | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US5795873A (en) * | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
US5594004A (en) * | 1993-03-17 | 1997-01-14 | Meiji Seika Kabushiki Kaisha | Compound with platelet aggregation inhibitor activity |
US5441972A (en) * | 1993-04-02 | 1995-08-15 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical use of pyridoxal derivative |
US5504090A (en) * | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
US5858017A (en) * | 1994-12-12 | 1999-01-12 | Omeros Medical Systems, Inc. | Urologic irrigation solution and method for inhibition of pain, inflammation and spasm |
US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
US5874443A (en) * | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5874420A (en) * | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5770215A (en) * | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US5944020A (en) * | 1997-02-25 | 1999-08-31 | Cypros Pharmaceutical Corp. | Use of fructose-1 6-diphosphate as an inotrope drug after cardiopulmonary bypass surgery |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
US6544547B2 (en) * | 1997-07-14 | 2003-04-08 | N. V. Nutricia | Nutritional composition containing methionine |
US6358960B1 (en) * | 1998-02-17 | 2002-03-19 | Ono Pharmaceutical Co., Ltd. | Amidino derivatives and drugs containing the same as the active ingredient |
US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
US6789997B2 (en) * | 1998-06-08 | 2004-09-14 | Stevedoring Services Of America, Inc. | Method and apparatus for pallet removal cargo queuing and stowage of stacks of cartons of frozen animal products |
US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
US6051585A (en) * | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
US6274170B1 (en) * | 1999-02-18 | 2001-08-14 | Richard Heibel | Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same |
US6339085B1 (en) * | 1999-03-08 | 2002-01-15 | The University Of Manitoba | Therapeutics for cardiovascular and related diseases |
US6890943B2 (en) * | 1999-03-08 | 2005-05-10 | Medicure Inc. | Pyridoxal analogues and methods of treatment |
US7230009B2 (en) * | 1999-03-08 | 2007-06-12 | Medicure, Inc. | Pyridoxal analogues and methods of treatment |
US6677356B1 (en) * | 1999-08-24 | 2004-01-13 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US6867215B2 (en) * | 2000-02-29 | 2005-03-15 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US7105673B2 (en) * | 2000-02-29 | 2006-09-12 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6605612B2 (en) * | 2000-02-29 | 2003-08-12 | Medicure International Inc. | Cardioprotective phosohonates and malonates |
US20040171588A1 (en) * | 2000-02-29 | 2004-09-02 | Wasimul Haque | Cardioprotective phosphonates and malonates |
US20030114424A1 (en) * | 2000-03-28 | 2003-06-19 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6861439B2 (en) * | 2000-03-28 | 2005-03-01 | Medicure International, Inc. | Treatment of cerebrovascular disease |
US6586414B2 (en) * | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
US20050107443A1 (en) * | 2000-07-07 | 2005-05-19 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US6417204B1 (en) * | 2000-07-07 | 2002-07-09 | Medicure International Inc. | Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics |
US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6548519B1 (en) * | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
US20070167411A1 (en) * | 2003-03-27 | 2007-07-19 | Medicure International Inc. | Compositions for treating angina |
US20070032456A1 (en) * | 2003-03-27 | 2007-02-08 | Friesen Albert D | Modulation of cell death |
US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20060035864A1 (en) * | 2004-08-10 | 2006-02-16 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20060094761A1 (en) * | 2004-10-28 | 2006-05-04 | Wasimul Haque | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
US20060094748A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
US20060148763A1 (en) * | 2005-01-05 | 2006-07-06 | Friesen Albert D | Compounds and methods for regulating triglyceride levels |
US20070149485A1 (en) * | 2005-11-28 | 2007-06-28 | Medicure International, Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008847A1 (en) * | 1999-07-13 | 2003-01-09 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US20090018052A1 (en) * | 1999-07-13 | 2009-01-15 | Medicure, Inc. | Treatment of Diabetes and Related Pathologies |
US20040171588A1 (en) * | 2000-02-29 | 2004-09-02 | Wasimul Haque | Cardioprotective phosphonates and malonates |
US20050107443A1 (en) * | 2000-07-07 | 2005-05-19 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US20060241083A1 (en) * | 2003-03-17 | 2006-10-26 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
US20070032456A1 (en) * | 2003-03-27 | 2007-02-08 | Friesen Albert D | Modulation of cell death |
US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
US20060094761A1 (en) * | 2004-10-28 | 2006-05-04 | Wasimul Haque | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20080306108A1 (en) * | 2004-10-28 | 2008-12-11 | Medicure International Inc. | Substituted Pyridoxines As Anti-Platelet Agents |
US20060094748A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
US7812037B2 (en) | 2004-10-28 | 2010-10-12 | Medicure International, Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20070243249A1 (en) * | 2004-11-26 | 2007-10-18 | Friesen Albert D | Novel formulation of pyridoxal-5'-phosphate and method of preparation |
US20080213364A1 (en) * | 2004-11-26 | 2008-09-04 | Medicure International, Inc. | Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation |
US20060148763A1 (en) * | 2005-01-05 | 2006-07-06 | Friesen Albert D | Compounds and methods for regulating triglyceride levels |
US7375112B2 (en) | 2005-01-05 | 2008-05-20 | Medicure International Inc. | Compounds and methods for regulating triglyceride levels |
US20090018106A1 (en) * | 2005-03-30 | 2009-01-15 | Medicure International Inc. | Intravenous formulations of pyridoxal 5'- phosphate and method of preparation |
US20070149485A1 (en) * | 2005-11-28 | 2007-06-28 | Medicure International, Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
Also Published As
Publication number | Publication date |
---|---|
JP2008517955A (en) | 2008-05-29 |
US7459468B2 (en) | 2008-12-02 |
AU2005299220A1 (en) | 2006-05-04 |
US20060094748A1 (en) | 2006-05-04 |
EP1824826A1 (en) | 2007-08-29 |
EP1824826A4 (en) | 2009-06-03 |
WO2006045204A1 (en) | 2006-05-04 |
CA2585177A1 (en) | 2006-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070142270A1 (en) | Aryl Sulfonic Pyridoxines as Antiplatelet Agents | |
US7812037B2 (en) | Dual antiplatelet/anticoagulant pyridoxine analogs | |
US20080306108A1 (en) | Substituted Pyridoxines As Anti-Platelet Agents | |
US5612378A (en) | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors | |
US7417144B2 (en) | Factor Xa inhibitors | |
US8524907B2 (en) | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | |
US6417204B1 (en) | Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics | |
CZ381397A3 (en) | ARTYLSULFONYLAMINOBENZENE DERIVATIVES AND THEIR USE AS Xa FACTOR INHIBITORS | |
US9975874B2 (en) | Factor XIa inhibitors | |
RU2712268C2 (en) | XIa FACTOR INHIBITORS | |
US10472344B2 (en) | Factor XIa inhibitors | |
EP1086099B1 (en) | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
NO312834B1 (en) | Compounds and pharmaceutical compositions containing said compound useful in the treatment of a human with a disease condition characterized by thrombotic action | |
JP2008521844A (en) | Cyclic iminocarbamates and their use | |
US20080051388A1 (en) | Novel Compounds That Inhibit Factor Xa Activity | |
US20110195997A1 (en) | Dicarboxamide Derivatives | |
CA3089970A1 (en) | Therapeutic compounds and compositions | |
EP1526131A1 (en) | Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors | |
US20240101567A1 (en) | Factor xia inhibitors | |
US20080103143A1 (en) | Novel heteroaryl carboxamides | |
TW200530216A (en) | New 5,6-dihydropyridin-2-one compounds useful as inhibitors of thrombin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |